subject_id,property_id,property_label,property_description,property_uri,object_id,subject_qid,property_pid,object_qid,reference_uri,reference_supporting_text,reference_date,property_term,subject_type,object_type,subject_term,object_term,prevalence,curation_evidence,curation_date,curator_uri,comments
NCBIGene:358,RO:0002331,involved in,NA,NA,KEGG-path:map04976,Q14905238,P361,Q30039518,NA,NA,NA,participates,gene,pathway,AQP1,Bile secretion,NA,https://monarchinitiative.org/gene/NCBIGene%3A358#pathways,2017-11-16,http://orcid.org/0000-0003-0169-8159,I have only included the pathways from KEGG that seems are not retrievable edges from the Monarch API.
NCBIGene:358,RO:0002331,involved in,NA,NA,KEGG-path:map04964,Q14905238,P361,Q30039529,NA,NA,NA,participates,gene,pathway,AQP1,Proximal tubule bicarbonate reclamation,NA,https://monarchinitiative.org/gene/NCBIGene%3A358#pathways,2017-11-16,http://orcid.org/0000-0003-0169-8159,I have only included the pathways from KEGG that seems are not retrievable edges from the Monarch API.
NCBIGene:358,RO:0002331,involved in,NA,NA,KEGG-path:maphsa04924,Q14905238,P361,NA,NA,NA,NA,participates,gene,pathway,AQP1,Renin secretion,NA,https://monarchinitiative.org/gene/NCBIGene%3A358#pathways,2017-11-16,http://orcid.org/0000-0003-0169-8159,I have only included the pathways from KEGG that seems are not retrievable edges from the Monarch API.
NCBIGene:358,RO:0002205,has gene product,NA,NA,UniProt:P29972,Q14905238,P688,Q2083074,NA,NA,NA,encodes,gene,protein,AQP1,NA,NA,NA,2017-11-16,http://orcid.org/0000-0003-0169-8159,NA
NCBIGene:343,RO:0002205,has gene product,NA,NA,UniProt:O94778,Q17830654,P688,Q21106460,NA,NA,NA,encodes,gene,protein,AQP1,NA,NA,NA,2017-11-16,http://orcid.org/0000-0003-0169-8159,NA
NCBIGene:359,RO:0002205,has gene product,NA,NA,UniProt:P41181,Q14902527,P688,Q2045854,NA,NA,NA,encodes,gene,protein,AQP1,NA,NA,NA,2017-11-16,http://orcid.org/0000-0003-0169-8159,NA
NCBIGene:361,RO:0002205,has gene product,NA,NA,UniProt:P55087,Q14902502,P688,Q3820749,NA,NA,NA,encodes,gene,protein,AQP1,NA,NA,NA,2017-11-16,http://orcid.org/0000-0003-0169-8159,NA
NCBIGene:362,RO:0002205,has gene product,NA,NA,UniProt:P55064,Q17831317,P688,Q21106470,NA,NA,NA,encodes,gene,protein,AQP1,NA,NA,NA,2017-11-16,http://orcid.org/0000-0003-0169-8159,NA
NCBIGene:363,RO:0002205,has gene product,NA,NA,UniProt:Q13520,Q17831370,P688,Q21106475,NA,NA,NA,encodes,gene,protein,AQP1,NA,NA,NA,2017-11-16,http://orcid.org/0000-0003-0169-8159,NA
NCBIGene:4284,RO:0002205,has gene product,NA,NA,UniProt:P30301,Q18029134,P688,Q21122978,NA,NA,NA,encodes,gene,protein,AQP1,NA,NA,NA,2017-11-16,http://orcid.org/0000-0003-0169-8159,NA
UniProt:P29972,rdf:type,instance of,NA,NA,InterPro:IPR000425,Q2083074,P31,Q24786770,NA,NA,NA,instance_of,protein,protein family,NA,Major intrinsic protein,NA,NA,2017-11-16,http://orcid.org/0000-0003-0169-8159,NA
UniProt:O94778,rdf:type,instance of,NA,NA,InterPro:IPR000425,Q21106460,P31,Q24786770,NA,NA,NA,instance_of,protein,protein family,NA,Major intrinsic protein,NA,NA,2017-11-16,http://orcid.org/0000-0003-0169-8159,NA
UniProt:P41181,rdf:type,instance of,NA,NA,InterPro:IPR000425,Q2045854,P31,Q24786770,NA,NA,NA,instance_of,protein,protein family,NA,Major intrinsic protein,NA,NA,2017-11-16,http://orcid.org/0000-0003-0169-8159,NA
UniProt:P55087,rdf:type,instance of,NA,NA,InterPro:IPR000425,Q3820749,P31,Q24786770,NA,NA,NA,instance_of,protein,protein family,NA,Major intrinsic protein,NA,NA,2017-11-16,http://orcid.org/0000-0003-0169-8159,NA
UniProt:P55064,rdf:type,instance of,NA,NA,InterPro:IPR000425,Q21106470,P31,Q24786770,NA,NA,NA,instance_of,protein,protein family,NA,Major intrinsic protein,NA,NA,2017-11-16,http://orcid.org/0000-0003-0169-8159,NA
UniProt:Q13520,rdf:type,instance of,NA,NA,InterPro:IPR000425,Q21106475,P31,Q24786770,NA,NA,NA,instance_of,protein,protein family,NA,Major intrinsic protein,NA,NA,2017-11-16,http://orcid.org/0000-0003-0169-8159,NA
UniProt:P30301,rdf:type,instance of,NA,NA,InterPro:IPR000425,Q21122978,P31,Q24786770,NA,NA,NA,instance_of,protein,protein family,NA,Major intrinsic protein,NA,NA,2017-11-16,http://orcid.org/0000-0003-0169-8159,NA
NCBIGene:55768,RO:0002200,has phenotype,NA,NA,DOID:0060728,Q18042037,P2293,Q28024539,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"NGLY1 deficiency (OMIM 610661 and 615273), or NGLY1-CDDG, was first reported in 2012 by Need et al., who, through exome sequencing, identified biallelic mutations in the NGLY1 gene as the cause of disease in one child.",2016-07-07,associates,gene,disease,NGLY1 gene,NGLY1 deficiency,NA,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
HGVS:NM_018297.3:c.1201A>T,GENO:0000418,has affected feature,NA,NA,NCBIGene:55768,Q29016913,P3433,Q18042037,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"NGLY1 deficiency (OMIM 610661 and 615273), or NGLY1-CDDG, was first reported in 2012 by Need et al., who, through exome sequencing, identified biallelic mutations in the NGLY1 gene as the cause of disease in one child. NGLY1 encodes N-glycanase 1, an enzyme involved in the cytosolic degradation of misfolded glycoproteins and other glycoproteins bound for degradation. In the index case, a 3-year-old boy inherited a maternal c.1891delC (p.Q631SNM_018297.3) variant and a paternal c.1201A>T (p.R401*NM_018297.3) variant.",2016-07-07,in_gene,variant,gene,c.1201A>T,NGLY1 gene,NA,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
HGVS:NM_018297.3:c.1201A>T,RO:0002200,has phenotype,NA,NA,DOID:0060728,Q29016913,P2293,Q28024539,https://www.ncbi.nlm.nih.gov/pubmed/27388694,All five individuals carrying the common mutation c.1201A>T were either moderately or severely impaired; those carrying at least one copy had a higher mean score (36) than those without (20.5) (p = 0.0184).,2016-07-07,associates,variant,disease,c.1201A>T,NGLY1 deficiency,NA,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
NCBIGene:55768,RO:0002205,has gene product,NA,NA,UniProt:Q96IV0,Q18042037,P688,Q21119040,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"The cytosolic enzyme N-glycanase 1, encoded by NGLY1, catalyzes cleavage of the B-aspartyl glycosylamine bond of N-linked glycoproteins, releasing intact N-glycans from proteins bound for degradation.",2016-07-07,encodes,gene,protein,NGLY1,N-Glycanase 1,NA,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
UniProt:Q96IV0,RO:0002331,involved in,NA,NA,GO:0006515,Q21119040,P682,Q21108009,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"NGLY1 encodes N-glycanase 1, an enzyme involved in the cytosolic degradation of misfolded glycoproteins and other glycoproteins bound for degradation.",2016-07-07,participates,protein,biological process,N-Glycanase 1,cytosolic degradation of misfolded glycoproteins and other glycoproteins bound for degradation.,NA,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
UniProt:Q96IV0,RO:0002331,involved in,NA,NA,GO:0006516,Q21119040,P682,Q21101373,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"NGLY1 encodes N-glycanase 1, an enzyme involved in the cytosolic degradation of misfolded glycoproteins and other glycoproteins bound for degradation.",2016-07-07,participates,protein,biological process,N-Glycanase 1,cytosolic degradation of misfolded glycoproteins and other glycoproteins bound for degradation.,NA,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
UniProt:Q96IV0,RO:0002331,involved in,NA,NA,GO:0006517,Q21119040,P682,Q14905965,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"NGLY1 encodes N-glycanase 1, an enzyme involved in the cytosolic degradation of misfolded glycoproteins and other glycoproteins bound for degradation.",2016-07-07,participates,protein,biological process,N-Glycanase 1,cytosolic degradation of misfolded glycoproteins and other glycoproteins bound for degradation.,NA,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
UniProt:Q96IV0,RO:0002327,enables,NA,NA,GO:0000224,Q21119040,P680,Q21119039,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"The cytosolic enzyme N-glycanase 1, encoded by NGLY1, catalyzes cleavage of the B-aspartyl glycosylamine bond of N-linked glycoproteins, releasing intact N-glycans from proteins bound for degradation.",2016-07-07,molecular_activity,protein,molecular function,N-Glycanase 1,"cleavage of the B-aspartyl glycosylamine bond of N-linked glycoproteins, releasing intact N-glycans from proteins bound for degradation.",NA,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
UniProt:Q96IV0,BFO:0000050,is part of,NA,NA,GO:0005829,Q21119040,P681,Q220599,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"The cytosolic enzyme N-glycanase 1, encoded by NGLY1, catalyzes cleavage of the B-aspartyl glycosylamine bond of N-linked glycoproteins, releasing intact N-glycans from proteins bound for degradation.",2016-07-07,in_cell_component,protein,cell component,N-Glycanase 1,cytosol,NA,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
UniProt:Q96IV0,RO:0002206,expressed in,NA,NA,CL:0000738,Q21119040,P2293,Q42395,https://www.ncbi.nlm.nih.gov/pubmed/27388694,NGLY1 protein expression in leukocytes was reduced in the parents and undetectable in the proband compared with controls.,2016-07-07,down_protein_expression_in,protein,anatomy,NGLY1 protein,leukocytes,NA,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
GO:0006517,RO:0002200,has phenotype,NA,NA,DOID:0060728,Q14905965,P2293,Q28024539,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Although more than 100 different congenital disorders of glycosylatoin (CDGs) have been reported since the first description by Jaeken et al. in 1980, only one congenital disorder of deglycosilation has been described. NGLY1 deficiency (OMIM 610661 and 615273), or NGLY1-CDDG, was first reported in 2012 by Need et al., who, through exome sequencing, identified biallelic mutations in the NGLY1 gene as the cause of disease in one child.",2016-07-07,associates,biological process,disease,deglycosilation,NGLY1 deficiency,NA,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0001999 ,Q28024539,P1557,Q29019704,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Our prospective investigations into NGLY1-CDDG revealed several new discoveries associated with this disorder.(...). We also confirmed and further detailed the global developmental delay, movement disorder, frequent seizure disorder, hypotonia, hypolacrima or alacrima, corneal disease, ptosis, lagophthalmous, strabismus, peripheral neuropathy and occasional diminished reflexes, hypohidrosis, auditory brainstem response abnormalities, abnormal brain imaging, scoliosis, acquired microcephaly, small hands and feet, dysmorphic features, constipation, elevated liver enzymes present only early in childhood, osteopenia, and hypocholesterolemia associated with NGLY1-CDDG. ",2016-07-07,presents,disease,phenotype,NGLY1 deficiency,dysmorphic features,discussion,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0000297,Q28024539,P1557,Q29642554,https://www.ncbi.nlm.nih.gov/pubmed/27388694,Most affected individuals had hypotonic facies. ,2016-07-07,presents,disease,phenotype,NGLY1 deficiency,hypotonic facies (dysmorphology) ,12/12,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0004325 ,Q28024539,P1557,Q29642619,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Our prospective investigations into NGLY1-CDDG revealed several new discoveries associated with this disorder. These include low CSF total protein and albumin, optic atrophy and retinal pigmentary changes/cone distrophy, poor weight gain starting in mid-childhood, lower than predicted resting energy expenditure, central and obstructive sleep apnea, delayed bone age, joint hypermobility, progressive brain atrophy, abnormalities in MRS-measured metabolites, various abnormalities on skeletal survey, high antibody titers after rubella and rubeola vaccination, and low levels of several pro-coagulation and anti-coagulation factors.",2016-07-07,presents,disease,phenotype,NGLY1 deficiency,low weight,NA,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0000275 ,Q28024539,P1557,Q29642692,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"The features of older individuals reflected their low weight, with thin facies, hollowed cheeks, and visible zygomatic arches.",2016-07-07,presents,disease,phenotype,NGLY1 deficiency,thin facies,NA,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0009938 ,Q28024539,P1557,Q29642730,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"The features of older individuals reflected their low weight, with thin facies, hollowed cheeks, and visible zygomatic arches.",2016-07-07,presents,disease,phenotype,NGLY1 deficiency,hollowed cheeks,NA,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0012370,Q28024539,P1557,NA,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"The features of older individuals reflected their low weight, with thin facies, hollowed cheeks, and visible zygomatic arches.",2016-07-07,presents,disease,phenotype,NGLY1 deficiency,visible zygomatic arches,NA,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0000463 ,Q28024539,P1557,Q29642988,https://www.ncbi.nlm.nih.gov/pubmed/27388694,Figure 2,2016-07-07,presents,disease,phenotype,NGLY1 deficiency,upturned nasal tip,NA,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0000508 ,Q28024539,P1557,Q622427,https://www.ncbi.nlm.nih.gov/pubmed/27388694,Figure 2,2016-07-07,presents,disease,clinical feature,NGLY1 deficiency,ptosis,NA,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0000248 ,Q28024539,P1557,Q42649,https://www.ncbi.nlm.nih.gov/pubmed/27388694,Figure 2,2016-07-07,presents,disease,phenotype,NGLY1 deficiency,brachycephaly,NA,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0005484 ,Q28024539,P1557,Q29643000,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Our prospective investigations into NGLY1-CDDG revealed several new discoveries associated with this disorder.(...). We also confirmed and further detailed the global developmental delay, movement disorder, frequent seizure disorder, hypotonia, hypolacrima or alacrima, corneal disease, ptosis, lagophthalmous, strabismus, peripheral neuropathy and occasional diminished reflexes, hypohidrosis, auditory brainstem response abnormalities, abnormal brain imaging, scoliosis, acquired microcephaly, small hands and feet, dysmorphic features, constipation, elevated liver enzymes present only early in childhood, osteopenia, and hypocholesterolemia associated with NGLY1-CDDG. ",2016-07-07,presents,disease,phenotype,NGLY1 deficiency,acquired microcephaly,4/12,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0001773,Q28024539,P1557,Q29019700,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Our prospective investigations into NGLY1-CDDG revealed several new discoveries associated with this disorder.(...). We also confirmed and further detailed the global developmental delay, movement disorder, frequent seizure disorder, hypotonia, hypolacrima or alacrima, corneal disease, ptosis, lagophthalmous, strabismus, peripheral neuropathy and occasional diminished reflexes, hypohidrosis, auditory brainstem response abnormalities, abnormal brain imaging, scoliosis, acquired microcephaly, small hands and feet, dysmorphic features, constipation, elevated liver enzymes present only early in childhood, osteopenia, and hypocholesterolemia associated with NGLY1-CDDG. ",2016-07-07,presents,disease,phenotype,NGLY1 deficiency,short foot,12/12,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0001263,Q28024539,P1557,Q1142806,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"In this study, we describe the clinical spectrum of NGLY1 deficiency (NGLY1-CDDG). In 12 individuals ages 2 to 21 years with confirmed, biallelic, pathogenic NGLY1 mutations, we identified previously unreported clinical features, including optic atrophy and retinal pigmentary changes/cone distrophy, delayed bone age, joint hypermobility, and lower than predicted resting energy expenditure. Novel findings include low cerebral spinal fluid (CSF) total protein and albumin and unusually high antibody titers toward rubella and/or rubeola following vaccination. We also confirmed and further quantified previously reported findings noting that decreased tear production, transient transaminitis, small feet, a complex hyperkinetic movement disorder, and varying degrees of global developmental delay with relatively preserved socialization are the most consistent features.",2016-07-07,presents,disease,phenotype,NGLY1 deficiency,developmental delay,12/12,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0001249 ,Q28024539,P1557,Q183560,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"All 12 subjects had at least some developmental delay or intellectual disability, with a broad range of severity (Table 1 and Supplemental Table S1 online).",2016-07-07,presents,disease,phenotype,NGLY1 deficiency,intellectual disability,12/12,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0004302 ,Q28024539,P1557,Q29643060,https://www.ncbi.nlm.nih.gov/pubmed/27388694,Motor deficits were also reflected in impaired daily living skills scores.,2016-07-07,presents,disease,phenotype,NGLY1 deficiency,motor deficits,12/12,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0031058,Q28024539,P1557,NA,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"On the Vineland Adaptative Behavior Scales (second edition), composite scores ranged from 24 to 98, with a mean of 51 (SEM=7). (Table 1 and Supplemental Table S1 online). Table 1 caption: Vineland Adaptative Behavior Scales composite score; in a normal population, the mean is 100 and standard deviation is 15.",2016-07-07,presents,disease,phenotype,NGLY1 deficiency,"Low Vineland Adaptative Behaviour score (mean=51, SEM=7) or impaired daily living skills",12/12,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0001250,Q28024539,P1557,Q6279182,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Our prospective investigations into NGLY1-CDDG revealed several new discoveries associated with this disorder.(...). We also confirmed and further detailed the global developmental delay, movement disorder, frequent seizure disorder, hypotonia, hypolacrima or alacrima, corneal disease, ptosis, lagophthalmous, strabismus, peripheral neuropathy and occasional diminished reflexes, hypohidrosis, auditory brainstem response abnormalities, abnormal brain imaging, scoliosis, acquired microcephaly, small hands and feet, dysmorphic features, constipation, elevated liver enzymes present only early in childhood, osteopenia, and hypocholesterolemia associated with NGLY1-CDDG. ",2016-07-07,presents,disease,phenotype,NGLY1 deficiency,seizures,7/12,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0010841 ,Q28024539,P1557,Q29643234,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"On overnight EEG, only one individual (patient 6) had active seizures recorded, but seven had multifocal epileptiform activity.",2016-07-07,presents,disease,phenotype,NGLY1 deficiency,multifocal epileptiform activity,7/12,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0004305,Q28024539,P1557,Q2608695,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"In this study, we describe the clinical spectrum of NGLY1 deficiency (NGLY1-CDDG). In 12 individuals ages 2 to 21 years with confirmed, biallelic, pathogenic NGLY1 mutations, we identified previously unreported clinical features, including optic atrophy and retinal pigmentary changes/cone distrophy, delayed bone age, joint hypermobility, and lower than predicted resting energy expenditure. Novel findings include low cerebral spinal fluid (CSF) total protein and albumin and unusually high antibody titers toward rubella and/or rubeola following vaccination. We also confirmed and further quantified previously reported findings noting that decreased tear production, transient transaminitis, small feet, a complex hyperkinetic movement disorder, and varying degrees of global developmental delay with relatively preserved socialization are the most consistent features.",2016-07-07,presents,disease,phenotype,NGLY1 deficiency,"hyperkinetic movement disorder (inlcude choreiform, athetoid, dystonic, myoclonic, action tremor, and dysmetric movements)",12/12,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0002072 ,Q28024539,P1557,Q1076421,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"All 12 individuals exhibited hyperkinetic movement disorders that included choreiform, athetoid, dystonic, myoclonic, action tremor, and dysmetric movements, and were more severe in younger individuals (Supplementary Movie S1 online).",2016-07-07,presents,disease,phenotype,NGLY1 deficiency,choreiform movements,NA,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0002305 ,Q28024539,P1557,Q755524,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"All 12 individuals exhibited hyperkinetic movement disorders that included choreiform, athetoid, dystonic, myoclonic, action tremor, and dysmetric movements, and were more severe in younger individuals (Supplementary Movie S1 online).",2016-07-07,presents,disease,phenotype,NGLY1 deficiency,athetoid movements,NA,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0001336 ,Q28024539,P1557,Q116275,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"All 12 individuals exhibited hyperkinetic movement disorders that included choreiform, athetoid, dystonic, myoclonic, action tremor, and dysmetric movements, and were more severe in younger individuals (Supplementary Movie S1 online).",2016-07-07,presents,disease,phenotype,NGLY1 deficiency,myoclonic movements,NA,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0002345 ,Q28024539,P1557,Q29643911,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"All 12 individuals exhibited hyperkinetic movement disorders that included choreiform, athetoid, dystonic, myoclonic, action tremor, and dysmetric movements, and were more severe in younger individuals (Supplementary Movie S1 online).",2016-07-07,presents,disease,phenotype,NGLY1 deficiency,action tremor,NA,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0001332 ,Q28024539,P1557,Q906492,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"All 12 individuals exhibited hyperkinetic movement disorders that included choreiform, athetoid, dystonic, myoclonic, action tremor, and dysmetric movements, and were more severe in younger individuals (Supplementary Movie S1 online).",2016-07-07,presents,disease,phenotype,NGLY1 deficiency,dystonic movements,NA,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0001310 ,Q28024539,P1557,Q517183,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"All 12 individuals exhibited hyperkinetic movement disorders that included choreiform, athetoid, dystonic, myoclonic, action tremor, and dysmetric movements, and were more severe in younger individuals (Supplementary Movie S1 online).",2016-07-07,presents,disease,phenotype,NGLY1 deficiency,dysmetric movements,NA,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0012448,Q28024539,P1557,Q29643664,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Delayed myelination was present in three of the four youngest individuals, but all the older individuals had complete myelination.",2016-07-07,presents,disease,laboratory findings,NGLY1 deficiency,delayed myelination,3/11,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0012444 ,Q28024539,P1557,Q29643693,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Our prospective investigations into NGLY1-CDDG revealed several new discoveries associated with this disorder. These include low CSF total protein and albumin, optic atrophy and retinal pigmentary changes/cone distrophy, poor weight gain starting in mid-childhood, lower than predicted resting energy expenditure, central and obstructive sleep apnea, delayed bone age, joint hypermobility, progressive brain atrophy, abnormalities in MRS-measured metabolites, various abnormalities on skeletal survey, high antibody titers after rubella and rubeola vaccination, and low levels of several pro-coagulation and anti-coagulation factors.",2016-07-07,presents,disease,laboratory findings,NGLY1 deficiency,"cerebral or brain atrophy (Brain MRI, MRS)",6/9,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0001272,Q28024539,P1557,Q29643762,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Four individuals (patients 1, 2, 6 and 10) also had slight cerebellar atrophy.",2016-07-07,presents,disease,laboratory findings,NGLY1 deficiency,"slight cerebellar atrophy (Brain MRI, MRS)",4/11,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0012705 ,Q28024539,P1557,Q29643776,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Our prospective investigations into NGLY1-CDDG revealed several new discoveries associated with this disorder. These include low CSF total protein and albumin, optic atrophy and retinal pigmentary changes/cone distrophy, poor weight gain starting in mid-childhood, lower than predicted resting energy expenditure, central and obstructive sleep apnea, delayed bone age, joint hypermobility, progressive brain atrophy, abnormalities in MRS-measured metabolites, various abnormalities on skeletal survey, high antibody titers after rubella and rubeola vaccination, and low levels of several pro-coagulation and anti-coagulation factors.",2016-07-07,presents,disease,laboratory findings,NGLY1 deficiency,abnormalities in brain MRS-measured metabolites,12/12,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0012708,Q28024539,P1557,NA,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Compared with the reference population, N-acetylaspartylglutamate plus N-acetylaspartate (NAA) was lower than normal in the left centrum semiovale (LCSO) (P = 0.004), the midline parietal gray matter (PGM) (P = 0.02), and superior cerebellar vermis (SVERM) (P < 0.0001). There was a deficit of glutamine plus glutamate plus gamma-aminobutyric acid (Glx) in the PGM (P = 0.03), LCSO (P = 0.01), and pons (P = 0.0002). Choline was higher than expected for age only in the LCSO (P = 0.0097), and myo-inositol was higher than expected for age in the pons (P = 0.002). Multiple correlations between these MRS-measured metabolites and age, functional assessments, brain volume, and neurotransmitters in the CSF were found (Supplementary Figure S3 online).",2016-07-07,presents,disease,laboratory findings,NGLY1 deficiency,low NAA in brain by MRS,12/12,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0030980,Q28024539,P1557,NA,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Compared with the reference population, N-acetylaspartylglutamate plus N-acetylaspartate (NAA) was lower than normal in the left centrum semiovale (LCSO) (P = 0.004), the midline parietal gray matter (PGM) (P = 0.02), and superior cerebellar vermis (SVERM) (P < 0.0001). There was a deficit of glutamine plus glutamate plus gamma-aminobutyric acid (Glx) in the PGM (P = 0.03), LCSO (P = 0.01), and pons (P = 0.0002). Choline was higher than expected for age only in the LCSO (P = 0.0097), and myo-inositol was higher than expected for age in the pons (P = 0.002). Multiple correlations between these MRS-measured metabolites and age, functional assessments, brain volume, and neurotransmitters in the CSF were found (Supplementary Figure S3 online).",2016-07-07,presents,disease,laboratory findings,NGLY1 deficiency,deficit of glutamine plus glutamate plus gamma-aminobutyric acid (Glx) in brain by MRS,12/12,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0031161,Q28024539,P1557,NA,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Compared with the reference population, N-acetylaspartylglutamate plus N-acetylaspartate (NAA) was lower than normal in the left centrum semiovale (LCSO) (P = 0.004), the midline parietal gray matter (PGM) (P = 0.02), and superior cerebellar vermis (SVERM) (P < 0.0001). There was a deficit of glutamine plus glutamate plus gamma-aminobutyric acid (Glx) in the PGM (P = 0.03), LCSO (P = 0.01), and pons (P = 0.0002). Choline was higher than expected for age only in the LCSO (P = 0.0097), and myo-inositol was higher than expected for age in the pons (P = 0.002). Multiple correlations between these MRS-measured metabolites and age, functional assessments, brain volume, and neurotransmitters in the CSF were found (Supplementary Figure S3 online).",2016-07-07,presents,disease,laboratory findings,NGLY1 deficiency,deficit of glutamine plus glutamate plus gamma-aminobutyric acid (Glx) in brain by MRS,12/12,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0500021,Q28024539,P1557,NA,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Compared with the reference population, N-acetylaspartylglutamate plus N-acetylaspartate (NAA) was lower than normal in the left centrum semiovale (LCSO) (P = 0.004), the midline parietal gray matter (PGM) (P = 0.02), and superior cerebellar vermis (SVERM) (P < 0.0001). There was a deficit of glutamine plus glutamate plus gamma-aminobutyric acid (Glx) in the PGM (P = 0.03), LCSO (P = 0.01), and pons (P = 0.0002). Choline was higher than expected for age only in the LCSO (P = 0.0097), and myo-inositol was higher than expected for age in the pons (P = 0.002). Multiple correlations between these MRS-measured metabolites and age, functional assessments, brain volume, and neurotransmitters in the CSF were found (Supplementary Figure S3 online).",2016-07-07,presents,disease,laboratory findings,NGLY1 deficiency,deficit of glutamine plus glutamate plus gamma-aminobutyric acid (Glx) in brain by MRS,12/12,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0012706 ,Q28024539,P1557,Q29643793,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Compared with the reference population, N-acetylaspartylglutamate plus N-acetylaspartate (NAA) was lower than normal in the left centrum semiovale (LCSO) (P = 0.004), the midline parietal gray matter (PGM) (P = 0.02), and superior cerebellar vermis (SVERM) (P < 0.0001). There was a deficit of glutamine plus glutamate plus gamma-aminobutyric acid (Glx) in the PGM (P = 0.03), LCSO (P = 0.01), and pons (P = 0.0002). Choline was higher than expected for age only in the LCSO (P = 0.0097), and myo-inositol was higher than expected for age in the pons (P = 0.002). Multiple correlations between these MRS-measured metabolites and age, functional assessments, brain volume, and neurotransmitters in the CSF were found (Supplementary Figure S3 online).",2016-07-07,presents,disease,laboratory findings,NGLY1 deficiency,High choline in brain by MRS,12/12,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0025460,Q28024539,P1557,NA,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Compared with the reference population, N-acetylaspartylglutamate plus N-acetylaspartate (NAA) was lower than normal in the left centrum semiovale (LCSO) (P = 0.004), the midline parietal gray matter (PGM) (P = 0.02), and superior cerebellar vermis (SVERM) (P < 0.0001). There was a deficit of glutamine plus glutamate plus gamma-aminobutyric acid (Glx) in the PGM (P = 0.03), LCSO (P = 0.01), and pons (P = 0.0002). Choline was higher than expected for age only in the LCSO (P = 0.0097), and myo-inositol was higher than expected for age in the pons (P = 0.002). Multiple correlations between these MRS-measured metabolites and age, functional assessments, brain volume, and neurotransmitters in the CSF were found (Supplementary Figure S3 online).",2016-07-07,presents,disease,laboratory findings,NGLY1 deficiency,High myo-inositol in brain by MRS,12/12,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0025457,Q28024539,P1557,NA,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Our prospective investigations into NGLY1-CDDG revealed several new discoveries associated with this disorder. These include low CSF total protein and albumin, optic atrophy and retinal pigmentary changes/cone distrophy, poor weight gain starting in mid-childhood, lower than predicted resting energy expenditure, central and obstructive sleep apnea, delayed bone age, joint hypermobility, progressive brain atrophy, abnormalities in MRS-measured metabolites, various abnormalities on skeletal survey, high antibody titers after rubella and rubeola vaccination, and low levels of several pro-coagulation and anti-coagulation factors.",2016-07-07,presents,disease,laboratory findings,NGLY1 deficiency,Low CSF total protein,9/9,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0025458,Q28024539,P1557,NA,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Our prospective investigations into NGLY1-CDDG revealed several new discoveries associated with this disorder. These include low CSF total protein and albumin, optic atrophy and retinal pigmentary changes/cone distrophy, poor weight gain starting in mid-childhood, lower than predicted resting energy expenditure, central and obstructive sleep apnea, delayed bone age, joint hypermobility, progressive brain atrophy, abnormalities in MRS-measured metabolites, various abnormalities on skeletal survey, high antibody titers after rubella and rubeola vaccination, and low levels of several pro-coagulation and anti-coagulation factors.",2016-07-07,presents,disease,laboratory findings,NGLY1 deficiency,Low CSF albumin,9/9,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0030978,Q28024539,P1557,NA,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"CSF total protein and albumin concentrations, as well as the CSF/serum albumin ratios, were low in nearly all individuals (Supplemental Table S3 online).",2016-07-07,presents,disease,laboratory findings,NGLY1 deficiency,Low CSF/serum albumin ratio,9/9,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0003785 ,Q28024539,P1557,Q29643837,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"In the two oldest subjects, CSF 5-hydroxyindolacetic acid (5-HIAA) and 5-homovanillic acid (HVA) were decreased, suggesting neuronal loss. Neopterin levels were normal but decreased with age, and CSF tetrahydrobiopterin (BH4) levels were below the lower limit of normal in all but one subject tested; however, there was not correlation with age. ",2016-07-07,presents,disease,laboratory findings,NGLY1 deficiency,decreased CSF HVA,2/9,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0025455,Q28024539,P1557,NA,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"In the two oldest subjects, CSF 5-hydroxyindolacetic acid (5-HIAA) and 5-homovanillic acid (HVA) were decreased, suggesting neuronal loss. Neopterin levels were normal but decreased with age, and CSF tetrahydrobiopterin (BH4) levels were below the lower limit of normal in all but one subject tested; however, there was not correlation with age. ",2016-07-07,presents,disease,laboratory findings,NGLY1 deficiency,decreased CSF 5-HIAA (5-hydroxyindolacetic acid),2/9,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0040209 ,Q28024539,P1557,Q29643842,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"In the two oldest subjects, CSF 5-hydroxyindolacetic acid (5-HIAA) and 5-homovanillic acid (HVA) were decreased, suggesting neuronal loss. Neopterin levels were normal but decreased with age, and CSF tetrahydrobiopterin (BH4) levels were below the lower limit of normal in all but one subject tested; however, there was not correlation with age. ",2016-07-07,presents,disease,laboratory findings,NGLY1 deficiency,low CSF BH4 (tetrahydrobiopterin),9/9,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0009830 ,Q28024539,P1557,Q18556979,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Our prospective investigations into NGLY1-CDDG revealed several new discoveries associated with this disorder.(...). We also confirmed and further detailed the global developmental delay, movement disorder, frequent seizure disorder, hypotonia, hypolacrima or alacrima, corneal disease, ptosis, lagophthalmous, strabismus, peripheral neuropathy and occasional diminished reflexes, hypohidrosis, auditory brainstem response abnormalities, abnormal brain imaging, scoliosis, acquired microcephaly, small hands and feet, dysmorphic features, constipation, elevated liver enzymes present only early in childhood, osteopenia, and hypocholesterolemia associated with NGLY1-CDDG. ",2016-07-07,presents,disease,clinical feature,NGLY1 deficiency,peripheral neuropathy,8/11,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0007141 ,Q28024539,P1557,NA,https://www.ncbi.nlm.nih.gov/pubmed/27388694,Nerve conduction studies were performed in 11 individuals (Supplementary Table S4 online). The predominant finding was an axonal sensorimotor polyneuropathy (n = 8) with additional demyelinative features (n = 6).,2016-07-07,presents,disease,clinical feature,NGLY1 deficiency,axonal sensorimotor polyneuropathy,8/11,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0007327 ,Q28024539,P1557,NA,https://www.ncbi.nlm.nih.gov/pubmed/27388694,Nerve conduction studies were performed in 11 individuals (Supplementary Table S4 online). The predominant finding was an axonal sensorimotor polyneuropathy (n = 8) with additional demyelinative features (n = 6).,2016-07-07,presents,disease,clinical feature,NGLY1 deficiency,axonal sensorimotor polyneuropathy with demyelinative features,6/11,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0012333,Q28024539,P1557,NA,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"QSWEATs, performed in 11 individuals, were abnormal in the same 8 individuals who had axonal sensorimotor neuropathies. The distal lower extremity QSWEAT was more frequently absent (7/11) compared with the forearm (1/11), consistent with a length-dependent neuropathy. ",2016-07-07,presents,disease,clinical feature,NGLY1 deficiency,abnormal QSWEATs,8/11,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0000522,Q28024539,P1557,Q19595845,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Our prospective investigations into NGLY1-CDDG revealed several new discoveries associated with this disorder.(...). We also confirmed and further detailed the global developmental delay, movement disorder, frequent seizure disorder, hypotonia, hypolacrima or alacrima, corneal disease, ptosis, lagophthalmous, strabismus, peripheral neuropathy and occasional diminished reflexes, hypohidrosis, auditory brainstem response abnormalities, abnormal brain imaging, scoliosis, acquired microcephaly, small hands and feet, dysmorphic features, constipation, elevated liver enzymes present only early in childhood, osteopenia, and hypocholesterolemia associated with NGLY1-CDDG. ",2016-07-07,presents,disease,clinical feature,NGLY1 deficiency,hypo- or complete alacrima,11/11,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0030001,Q28024539,P1557,NA,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Our prospective investigations into NGLY1-CDDG revealed several new discoveries associated with this disorder.(...). We also confirmed and further detailed the global developmental delay, movement disorder, frequent seizure disorder, hypotonia, hypolacrima or alacrima, corneal disease, ptosis, lagophthalmous, strabismus, peripheral neuropathy and occasional diminished reflexes, hypohidrosis, auditory brainstem response abnormalities, abnormal brain imaging, scoliosis, acquired microcephaly, small hands and feet, dysmorphic features, constipation, elevated liver enzymes present only early in childhood, osteopenia, and hypocholesterolemia associated with NGLY1-CDDG. ",2016-07-07,presents,disease,clinical feature,NGLY1 deficiency,lagophthalmous,11/11,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0000508 ,Q28024539,P1557,Q622427,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Our prospective investigations into NGLY1-CDDG revealed several new discoveries associated with this disorder.(...). We also confirmed and further detailed the global developmental delay, movement disorder, frequent seizure disorder, hypotonia, hypolacrima or alacrima, corneal disease, ptosis, lagophthalmous, strabismus, peripheral neuropathy and occasional diminished reflexes, hypohidrosis, auditory brainstem response abnormalities, abnormal brain imaging, scoliosis, acquired microcephaly, small hands and feet, dysmorphic features, constipation, elevated liver enzymes present only early in childhood, osteopenia, and hypocholesterolemia associated with NGLY1-CDDG. ",2016-07-07,presents,disease,clinical feature,NGLY1 deficiency,ptosis,11/11,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0000577 ,Q28024539,P1557,Q2556242,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Awake and sedated ophthalmic examinations were performed for 11 study participants (Supplementary Table S5 online). Lagophthalmus, ptosis, exotropia and/or esotropia, corneal neovascularization, pannus formation or scarring, optic nerve pallor or atrophy, retinal pigmentary changes including pigment granularity and pigmentary retinopathy or pigmentary changes, blonde or poorly pigmented retinal periphery, and refractive errors were observed (Figure 4).",2016-07-07,presents,disease,clinical feature,NGLY1 deficiency,exotropia and/or esotropia,11/11,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0000565 ,Q28024539,P1557,Q2720759,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Awake and sedated ophthalmic examinations were performed for 11 study participants (Supplementary Table S5 online). Lagophthalmus, ptosis, exotropia and/or esotropia, corneal neovascularization, pannus formation or scarring, optic nerve pallor or atrophy, retinal pigmentary changes including pigment granularity and pigmentary retinopathy or pigmentary changes, blonde or poorly pigmented retinal periphery, and refractive errors were observed (Figure 4).",2016-07-07,presents,disease,clinical feature,NGLY1 deficiency,exotropia and/or esotropia,11/11,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0011496 ,Q28024539,P1557,Q1266519,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Awake and sedated ophthalmic examinations were performed for 11 study participants (Supplementary Table S5 online). Lagophthalmus, ptosis, exotropia and/or esotropia, corneal neovascularization, pannus formation or scarring, optic nerve pallor or atrophy, retinal pigmentary changes including pigment granularity and pigmentary retinopathy or pigmentary changes, blonde or poorly pigmented retinal periphery, and refractive errors were observed (Figure 4).",2016-07-07,presents,disease,clinical feature,NGLY1 deficiency,corneal neovascularization,11/11,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0000559 ,Q28024539,P1557,Q1628473,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Awake and sedated ophthalmic examinations were performed for 11 study participants (Supplementary Table S5 online). Lagophthalmus, ptosis, exotropia and/or esotropia, corneal neovascularization, pannus formation or scarring, optic nerve pallor or atrophy, retinal pigmentary changes including pigment granularity and pigmentary retinopathy or pigmentary changes, blonde or poorly pigmented retinal periphery, and refractive errors were observed (Figure 4).",2016-07-07,presents,disease,clinical feature,NGLY1 deficiency,pannus formation or scarring,11/11,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0000648 ,Q28024539,P1557,Q18556970,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"In this study, we describe the clinical spectrum of NGLY1 deficiency (NGLY1-CDDG). In 12 individuals ages 2 to 21 years with confirmed, biallelic, pathogenic NGLY1 mutations, we identified previously unreported clinical features, including optic atrophy and retinal pigmentary changes/cone distrophy, delayed bone age, joint hypermobility, and lower than predicted resting energy expenditure. Novel findings include low cerebral spinal fluid (CSF) total protein and albumin and unusually high antibody titers toward rubella and/or rubeola following vaccination. We also confirmed and further quantified previously reported findings noting that decreased tear production, transient transaminitis, small feet, a complex hyperkinetic movement disorder, and varying degrees of global developmental delay with relatively preserved socialization are the most consistent features.",2016-07-07,presents,disease,clinical feature,NGLY1 deficiency,optic nerve pallor or atrophy,11/11,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0008051 ,Q28024539,P1557,Q29643939,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"In this study, we describe the clinical spectrum of NGLY1 deficiency (NGLY1-CDDG). In 12 individuals ages 2 to 21 years with confirmed, biallelic, pathogenic NGLY1 mutations, we identified previously unreported clinical features, including optic atrophy and retinal pigmentary changes/cone distrophy, delayed bone age, joint hypermobility, and lower than predicted resting energy expenditure. Novel findings include low cerebral spinal fluid (CSF) total protein and albumin and unusually high antibody titers toward rubella and/or rubeola following vaccination. We also confirmed and further quantified previously reported findings noting that decreased tear production, transient transaminitis, small feet, a complex hyperkinetic movement disorder, and varying degrees of global developmental delay with relatively preserved socialization are the most consistent features.",2016-07-07,presents,disease,clinical feature,NGLY1 deficiency,retinal pigmentary changes,11/11,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0000539,Q28024539,P1557,NA,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Awake and sedated ophthalmic examinations were performed for 11 study participants (Supplementary Table S5 online). Lagophthalmus, ptosis, exotropia and/or esotropia, corneal neovascularization, pannus formation or scarring, optic nerve pallor or atrophy, retinal pigmentary changes including pigment granularity and pigmentary retinopathy or pigmentary changes, blonde or poorly pigmented retinal periphery, and refractive errors were observed (Figure 4).",2016-07-07,presents,disease,clinical feature,NGLY1 deficiency,refractive errors,11/11,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0000548 ,Q28024539,P1557,Q29643945,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"In this study, we describe the clinical spectrum of NGLY1 deficiency (NGLY1-CDDG). In 12 individuals ages 2 to 21 years with confirmed, biallelic, pathogenic NGLY1 mutations, we identified previously unreported clinical features, including optic atrophy and retinal pigmentary changes/cone distrophy, delayed bone age, joint hypermobility, and lower than predicted resting energy expenditure. Novel findings include low cerebral spinal fluid (CSF) total protein and albumin and unusually high antibody titers toward rubella and/or rubeola following vaccination. We also confirmed and further quantified previously reported findings noting that decreased tear production, transient transaminitis, small feet, a complex hyperkinetic movement disorder, and varying degrees of global developmental delay with relatively preserved socialization are the most consistent features.",2016-07-07,presents,disease,clinical feature,NGLY1 deficiency,cone distrophy,1/1,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0006958,Q28024539,P1557,Q29019841,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Our prospective investigations into NGLY1-CDDG revealed several new discoveries associated with this disorder.(...). We also confirmed and further detailed the global developmental delay, movement disorder, frequent seizure disorder, hypotonia, hypolacrima or alacrima, corneal disease, ptosis, lagophthalmous, strabismus, peripheral neuropathy and occasional diminished reflexes, hypohidrosis, auditory brainstem response abnormalities, abnormal brain imaging, scoliosis, acquired microcephaly, small hands and feet, dysmorphic features, constipation, elevated liver enzymes present only early in childhood, osteopenia, and hypocholesterolemia associated with NGLY1-CDDG. ",2016-07-07,presents,disease,clinical feature,NGLY1 deficiency,transmission abnormality through the auditory brainstem,11/11,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0030906,Q28024539,P1557,NA,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Oral motor deficits, including persistent nutritive suckle swallow and poor oral bolus formation, were present in 10 of 11 subjects. Premature spillage and pharyngeal swallow response delays remained the primary deficits of all subjects.",2016-07-07,presents,disease,clinical feature,NGLY1 deficiency,persistent nutritive suckle swallow,10/11,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0031146,Q28024539,P1557,NA,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Oral motor deficits, including persistent nutritive suckle swallow and poor oral bolus formation, were present in 10 of 11 subjects. Premature spillage and pharyngeal swallow response delays remained the primary deficits of all subjects.",2016-07-07,presents,disease,clinical feature,NGLY1 deficiency,poor oral bolus,10/11,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0031162,Q28024539,P1557,NA,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Oral motor deficits, including persistent nutritive suckle swallow and poor oral bolus formation, were present in 10 of 11 subjects. Premature spillage and pharyngeal swallow response delays remained the primary deficits of all subjects.",2016-07-07,presents,disease,clinical feature,NGLY1 deficiency,Premature spillage and pharyngeal swallow response delays,11/11,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0002015,Q28024539,P1557,NA,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Oral motor deficits, including persistent nutritive suckle swallow and poor oral bolus formation, were present in 10 of 11 subjects. Premature spillage and pharyngeal swallow response delays remained the primary deficits of all subjects.",2016-07-07,presents,disease,clinical feature,NGLY1 deficiency,Premature spillage and pharyngeal swallow response delays,11/11,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0005216,Q28024539,P1557,NA,https://www.ncbi.nlm.nih.gov/pubmed/27388694,Development delays in mastication were evident and characterized by munching patterns without matured rotatory chewing of solid textures.,2016-07-07,presents,disease,clinical feature,NGLY1 deficiency,developmental delay in mastication,11/11,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0001649,Q28024539,P1557,NA,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Electrocardiogram results showed heart rates in the low 100s in all subjects (n = 12), with two individuals having QTcB>440 ms but a normal QTcF.",2016-07-07,presents,disease,clinical feature,NGLY1 deficiency,Electrocardiogram heart rates in the low 100s,12/12,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0010536 ,Q28024539,P1557,Q5062153,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Our prospective investigations into NGLY1-CDDG revealed several new discoveries associated with this disorder. These include low CSF total protein and albumin, optic atrophy and retinal pigmentary changes/cone distrophy, poor weight gain starting in mid-childhood, lower than predicted resting energy expenditure, central and obstructive sleep apnea, delayed bone age, joint hypermobility, progressive brain atrophy, abnormalities in MRS-measured metabolites, various abnormalities on skeletal survey, high antibody titers after rubella and rubeola vaccination, and low levels of several pro-coagulation and anti-coagulation factors.",2016-07-07,presents,disease,clinical feature,NGLY1 deficiency,central sleep apnea,1/9,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0002870 ,Q28024539,P1557,Q17083186,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Our prospective investigations into NGLY1-CDDG revealed several new discoveries associated with this disorder. These include low CSF total protein and albumin, optic atrophy and retinal pigmentary changes/cone distrophy, poor weight gain starting in mid-childhood, lower than predicted resting energy expenditure, central and obstructive sleep apnea, delayed bone age, joint hypermobility, progressive brain atrophy, abnormalities in MRS-measured metabolites, various abnormalities on skeletal survey, high antibody titers after rubella and rubeola vaccination, and low levels of several pro-coagulation and anti-coagulation factors.",2016-07-07,presents,disease,clinical feature,NGLY1 deficiency,obstructive sleep apnea,2/9,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0002019,Q28024539,P1557,Q178436,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Our prospective investigations into NGLY1-CDDG revealed several new discoveries associated with this disorder.(...). We also confirmed and further detailed the global developmental delay, movement disorder, frequent seizure disorder, hypotonia, hypolacrima or alacrima, corneal disease, ptosis, lagophthalmous, strabismus, peripheral neuropathy and occasional diminished reflexes, hypohidrosis, auditory brainstem response abnormalities, abnormal brain imaging, scoliosis, acquired microcephaly, small hands and feet, dysmorphic features, constipation, elevated liver enzymes present only early in childhood, osteopenia, and hypocholesterolemia associated with NGLY1-CDDG. ",2016-07-07,presents,disease,clinical feature,NGLY1 deficiency,constipation,10/12,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0001744 ,Q28024539,P1557,Q1129121,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Abnormalities in abdominal ultrasound included splenomegaly, steatosis, coarse or inhomogeneous liver texture, or hepatomegaly.",2016-07-07,presents,disease,clinical feature,NGLY1 deficiency,splenomegaly (abnormal abdominal ultrasound),6/12,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0001397 ,Q28024539,P1557,Q10863074,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Abnormalities in abdominal ultrasound included splenomegaly, steatosis, coarse or inhomogeneous liver texture, or hepatomegaly.",2016-07-07,presents,disease,clinical feature,NGLY1 deficiency,steatosis (abnormal abdominal ultrasound),6/12,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0031144,Q28024539,P1557,NA,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Abnormalities in abdominal ultrasound included splenomegaly, steatosis, coarse or inhomogeneous liver texture, or hepatomegaly.",2016-07-07,presents,disease,clinical feature,NGLY1 deficiency,coarse or inhomogeneous liver texture (abnormal abdominal ultrasound),6/12,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0002240 ,Q28024539,P1557,Q1362864,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Abnormalities in abdominal ultrasound included splenomegaly, steatosis, coarse or inhomogeneous liver texture, or hepatomegaly.",2016-07-07,presents,disease,clinical feature,NGLY1 deficiency,hepatomegaly (abnormal abdominal ultrasound),6/12,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0001395,Q28024539,P1557,Q147778,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Three of 12 had Fibroscan scores >7 kPa, which is the upper limit of normal, indicating possible liver fibrosis.",2016-07-07,presents,disease,clinical feature,NGLY1 deficiency,possible liver fibrosis,3/12,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0012340 ,Q28024539,P1557,Q29647375,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"In this study, we describe the clinical spectrum of NGLY1 deficiency (NGLY1-CDDG). In 12 individuals ages 2 to 21 years with confirmed, biallelic, pathogenic NGLY1 mutations, we identified previously unreported clinical features, including optic atrophy and retinal pigmentary changes/cone distrophy, delayed bone age, joint hypermobility, and lower than predicted resting energy expenditure. Novel findings include low cerebral spinal fluid (CSF) total protein and albumin and unusually high antibody titers toward rubella and/or rubeola following vaccination. We also confirmed and further quantified previously reported findings noting that decreased tear production, transient transaminitis, small feet, a complex hyperkinetic movement disorder, and varying degrees of global developmental delay with relatively preserved socialization are the most consistent features.",2016-07-07,presents,disease,clinical feature,NGLY1 deficiency,low resting energy expenditure,9/12,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0002910 ,Q28024539,P1557,Q2448873,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Our prospective investigations into NGLY1-CDDG revealed several new discoveries associated with this disorder.(...). We also confirmed and further detailed the global developmental delay, movement disorder, frequent seizure disorder, hypotonia, hypolacrima or alacrima, corneal disease, ptosis, lagophthalmous, strabismus, peripheral neuropathy and occasional diminished reflexes, hypohidrosis, auditory brainstem response abnormalities, abnormal brain imaging, scoliosis, acquired microcephaly, small hands and feet, dysmorphic features, constipation, elevated liver enzymes present only early in childhood, osteopenia, and hypocholesterolemia associated with NGLY1-CDDG. ",2016-07-07,presents,disease,laboratory findings,NGLY1 deficiency,elevations in aspartate aminotransferase and/or alanine transaminase,8/8,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0003146 ,Q28024539,P1557,Q10295810,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Our prospective investigations into NGLY1-CDDG revealed several new discoveries associated with this disorder.(...). We also confirmed and further detailed the global developmental delay, movement disorder, frequent seizure disorder, hypotonia, hypolacrima or alacrima, corneal disease, ptosis, lagophthalmous, strabismus, peripheral neuropathy and occasional diminished reflexes, hypohidrosis, auditory brainstem response abnormalities, abnormal brain imaging, scoliosis, acquired microcephaly, small hands and feet, dysmorphic features, constipation, elevated liver enzymes present only early in childhood, osteopenia, and hypocholesterolemia associated with NGLY1-CDDG. ",2016-07-07,presents,disease,laboratory findings,NGLY1 deficiency,"low total cholesterol, LDL, and triglycerides",8/8,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0005543,Q28024539,P1557,NA,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Our prospective investigations into NGLY1-CDDG revealed several new discoveries associated with this disorder. These include low CSF total protein and albumin, optic atrophy and retinal pigmentary changes/cone distrophy, poor weight gain starting in mid-childhood, lower than predicted resting energy expenditure, central and obstructive sleep apnea, delayed bone age, joint hypermobility, progressive brain atrophy, abnormalities in MRS-measured metabolites, various abnormalities on skeletal survey, high antibody titers after rubella and rubeola vaccination, and low levels of several pro-coagulation and anti-coagulation factors.",2016-07-07,presents,disease,phenotype,NGLY1 deficiency,"low coagulation protein C activity, factor II, IX, XI, and fibrinogen",6/12,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0011900,Q28024539,P1557,NA,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Our prospective investigations into NGLY1-CDDG revealed several new discoveries associated with this disorder. These include low CSF total protein and albumin, optic atrophy and retinal pigmentary changes/cone distrophy, poor weight gain starting in mid-childhood, lower than predicted resting energy expenditure, central and obstructive sleep apnea, delayed bone age, joint hypermobility, progressive brain atrophy, abnormalities in MRS-measured metabolites, various abnormalities on skeletal survey, high antibody titers after rubella and rubeola vaccination, and low levels of several pro-coagulation and anti-coagulation factors.",2016-07-07,presents,disease,phenotype,NGLY1 deficiency,"low coagulation protein C activity, factor II, IX, XI, and fibrinogen",6/12,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0012201,Q28024539,P1557,NA,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Our prospective investigations into NGLY1-CDDG revealed several new discoveries associated with this disorder. These include low CSF total protein and albumin, optic atrophy and retinal pigmentary changes/cone distrophy, poor weight gain starting in mid-childhood, lower than predicted resting energy expenditure, central and obstructive sleep apnea, delayed bone age, joint hypermobility, progressive brain atrophy, abnormalities in MRS-measured metabolites, various abnormalities on skeletal survey, high antibody titers after rubella and rubeola vaccination, and low levels of several pro-coagulation and anti-coagulation factors.",2016-07-07,presents,disease,phenotype,NGLY1 deficiency,"low coagulation protein C activity, factor II, IX, XI, and fibrinogen",6/12,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0011858,Q28024539,P1557,NA,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Our prospective investigations into NGLY1-CDDG revealed several new discoveries associated with this disorder. These include low CSF total protein and albumin, optic atrophy and retinal pigmentary changes/cone distrophy, poor weight gain starting in mid-childhood, lower than predicted resting energy expenditure, central and obstructive sleep apnea, delayed bone age, joint hypermobility, progressive brain atrophy, abnormalities in MRS-measured metabolites, various abnormalities on skeletal survey, high antibody titers after rubella and rubeola vaccination, and low levels of several pro-coagulation and anti-coagulation factors.",2016-07-07,presents,disease,phenotype,NGLY1 deficiency,"low coagulation protein C activity, factor II, IX, XI, and fibrinogen",6/12,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0001929,Q28024539,P1557,NA,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Our prospective investigations into NGLY1-CDDG revealed several new discoveries associated with this disorder. These include low CSF total protein and albumin, optic atrophy and retinal pigmentary changes/cone distrophy, poor weight gain starting in mid-childhood, lower than predicted resting energy expenditure, central and obstructive sleep apnea, delayed bone age, joint hypermobility, progressive brain atrophy, abnormalities in MRS-measured metabolites, various abnormalities on skeletal survey, high antibody titers after rubella and rubeola vaccination, and low levels of several pro-coagulation and anti-coagulation factors.",2016-07-07,presents,disease,phenotype,NGLY1 deficiency,"low coagulation protein C activity, factor II, IX, XI, and fibrinogen",6/12,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0002750 ,Q28024539,P1557,Q29647492,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"In this study, we describe the clinical spectrum of NGLY1 deficiency (NGLY1-CDDG). In 12 individuals ages 2 to 21 years with confirmed, biallelic, pathogenic NGLY1 mutations, we identified previously unreported clinical features, including optic atrophy and retinal pigmentary changes/cone distrophy, delayed bone age, joint hypermobility, and lower than predicted resting energy expenditure. Novel findings include low cerebral spinal fluid (CSF) total protein and albumin and unusually high antibody titers toward rubella and/or rubeola following vaccination. We also confirmed and further quantified previously reported findings noting that decreased tear production, transient transaminitis, small feet, a complex hyperkinetic movement disorder, and varying degrees of global developmental delay with relatively preserved socialization are the most consistent features.",2016-07-07,presents,disease,clinical feature,NGLY1 deficiency,delayed bone age,8/11,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0000938 ,Q28024539,P1557,NA,https://www.ncbi.nlm.nih.gov/pubmed/27388694,Femoral bone desnity was low in all nine individuals who underwent dual X-ray absorptiometry scanning (mean and SEM z-scores for 8 patients younger than 21 years adjacent to the growth plate = -3 and 0.4; metaphysis-diaphysis = -2.2 and 0.6; and diaphysis = -1.8 and 0.5).,2016-07-07,presents,disease,clinical feature,NGLY1 deficiency,low femoral bone density,9/9,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0001382 ,Q28024539,P1557,Q29647501,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"In this study, we describe the clinical spectrum of NGLY1 deficiency (NGLY1-CDDG). In 12 individuals ages 2 to 21 years with confirmed, biallelic, pathogenic NGLY1 mutations, we identified previously unreported clinical features, including optic atrophy and retinal pigmentary changes/cone distrophy, delayed bone age, joint hypermobility, and lower than predicted resting energy expenditure. Novel findings include low cerebral spinal fluid (CSF) total protein and albumin and unusually high antibody titers toward rubella and/or rubeola following vaccination. We also confirmed and further quantified previously reported findings noting that decreased tear production, transient transaminitis, small feet, a complex hyperkinetic movement disorder, and varying degrees of global developmental delay with relatively preserved socialization are the most consistent features.",2016-07-07,presents,disease,clinical feature,NGLY1 deficiency,joint hypermobility,11/11,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0002673 ,Q28024539,P1557,Q955454,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Complete skeletal surveys were performed for 11 individuals; abnormalities included coxa valga (n = 11), scoliosis (n = 6), growth arrest lines or metaphyseal banding without palmidronate treatment (n = 4), dislocations or subluxations involving the hips and shoulder joints (n = 3), and sclerosis of the phalanges or tarsal bones (n = 2).",2016-07-07,presents,disease,clinical feature,NGLY1 deficiency,coxa valga (musculoskeletal abnormalities),11/11,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0002650,Q28024539,P1557,Q174857,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Our prospective investigations into NGLY1-CDDG revealed several new discoveries associated with this disorder.(...). We also confirmed and further detailed the global developmental delay, movement disorder, frequent seizure disorder, hypotonia, hypolacrima or alacrima, corneal disease, ptosis, lagophthalmous, strabismus, peripheral neuropathy and occasional diminished reflexes, hypohidrosis, auditory brainstem response abnormalities, abnormal brain imaging, scoliosis, acquired microcephaly, small hands and feet, dysmorphic features, constipation, elevated liver enzymes present only early in childhood, osteopenia, and hypocholesterolemia associated with NGLY1-CDDG. ",2016-07-07,presents,disease,clinical feature,NGLY1 deficiency,scoliosis ((musculoskeletal abnormalities),6/11,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0031164,Q28024539,P1557,NA,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Complete skeletal surveys were performed for 11 individuals; abnormalities included coxa valga (n = 11), scoliosis (n = 6), growth arrest lines or metaphyseal banding without palmidronate treatment (n = 4), dislocations or subluxations involving the hips and shoulder joints (n = 3), and sclerosis of the phalanges or tarsal bones (n = 2).",2016-07-07,presents,disease,clinical feature,NGLY1 deficiency,growth arrest lines or metaphyseal banding without palmidronate treatment (musculoskeletal abnormalities),4/11,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0003835,Q28024539,P1557,NA,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Complete skeletal surveys were performed for 11 individuals; abnormalities included coxa valga (n = 11), scoliosis (n = 6), growth arrest lines or metaphyseal banding without palmidronate treatment (n = 4), dislocations or subluxations involving the hips and shoulder joints (n = 3), and sclerosis of the phalanges or tarsal bones (n = 2).",2016-07-07,presents,disease,clinical feature,NGLY1 deficiency,dislocations or subluxations involving the hips and shoulder joints (musculoskeletal abnormalities),3/11,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0030043,Q28024539,P1557,NA,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Complete skeletal surveys were performed for 11 individuals; abnormalities included coxa valga (n = 11), scoliosis (n = 6), growth arrest lines or metaphyseal banding without palmidronate treatment (n = 4), dislocations or subluxations involving the hips and shoulder joints (n = 3), and sclerosis of the phalanges or tarsal bones (n = 2).",2016-07-07,presents,disease,clinical feature,NGLY1 deficiency,dislocations or subluxations involving the hips and shoulder joints (musculoskeletal abnormalities),3/11,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0031051,Q28024539,P1557,NA,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Complete skeletal surveys were performed for 11 individuals; abnormalities included coxa valga (n = 11), scoliosis (n = 6), growth arrest lines or metaphyseal banding without palmidronate treatment (n = 4), dislocations or subluxations involving the hips and shoulder joints (n = 3), and sclerosis of the phalanges or tarsal bones (n = 2).",2016-07-07,presents,disease,clinical feature,NGLY1 deficiency,sclerosis of the phalanges or tarsal bones (musculoskeletal abnormalities),2/11,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0100924,Q28024539,P1557,NA,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Complete skeletal surveys were performed for 11 individuals; abnormalities included coxa valga (n = 11), scoliosis (n = 6), growth arrest lines or metaphyseal banding without palmidronate treatment (n = 4), dislocations or subluxations involving the hips and shoulder joints (n = 3), and sclerosis of the phalanges or tarsal bones (n = 2).",2016-07-07,presents,disease,clinical feature,NGLY1 deficiency,sclerosis of the phalanges or tarsal bones (musculoskeletal abnormalities),2/11,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0012785,Q28024539,P1557,NA,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Findings noted only once included flexion deformity of the fingers, hallux valgus, sclerotic lesion of the distal femur, thinning of the fibulas, prominent apophyseal bone formation in the ileac crests and ischia, ulnar bowing, expansion of the cortexes in the proximal and middle phalanges in digits 2-4, widened phalanges, and shortened and widened metatarsals.",2016-07-07,presents,disease,clinical feature,NGLY1 deficiency,flexion deformity of the fingers (musculoskeletal abnormalities),1/11,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0001822 ,Q28024539,P1557,Q852574,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Findings noted only once included flexion deformity of the fingers, hallux valgus, sclerotic lesion of the distal femur, thinning of the fibulas, prominent apophyseal bone formation in the ileac crests and ischia, ulnar bowing, expansion of the cortexes in the proximal and middle phalanges in digits 2-4, widened phalanges, and shortened and widened metatarsals.",2016-07-07,presents,disease,clinical feature,NGLY1 deficiency,hallux valgus (musculoskeletal abnormalities),1/11,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0031107,Q28024539,P1557,NA,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Findings noted only once included flexion deformity of the fingers, hallux valgus, sclerotic lesion of the distal femur, thinning of the fibulas, prominent apophyseal bone formation in the ileac crests and ischia, ulnar bowing, expansion of the cortexes in the proximal and middle phalanges in digits 2-4, widened phalanges, and shortened and widened metatarsals.",2016-07-07,presents,disease,clinical feature,NGLY1 deficiency,thinning of the fibulas (musculoskeletal abnormalities),1/11,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0003174 ,Q28024539,P1557,NA,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Findings noted only once included flexion deformity of the fingers, hallux valgus, sclerotic lesion of the distal femur, thinning of the fibulas, prominent apophyseal bone formation in the ileac crests and ischia, ulnar bowing, expansion of the cortexes in the proximal and middle phalanges in digits 2-4, widened phalanges, and shortened and widened metatarsals.",2016-07-07,presents,disease,clinical feature,NGLY1 deficiency,prominent apophyseal bone formation in the ileac crests and ischia (musculoskeletal abnormalities),1/11,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0003031 ,Q28024539,P1557,Q29647525,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Findings noted only once included flexion deformity of the fingers, hallux valgus, sclerotic lesion of the distal femur, thinning of the fibulas, prominent apophyseal bone formation in the ileac crests and ischia, ulnar bowing, expansion of the cortexes in the proximal and middle phalanges in digits 2-4, widened phalanges, and shortened and widened metatarsals.",2016-07-07,presents,disease,clinical feature,NGLY1 deficiency,ulnar bowing (musculoskeletal abnormalities),1/11,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0006009 ,Q28024539,P1557,Q29647624,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Findings noted only once included flexion deformity of the fingers, hallux valgus, sclerotic lesion of the distal femur, thinning of the fibulas, prominent apophyseal bone formation in the ileac crests and ischia, ulnar bowing, expansion of the cortexes in the proximal and middle phalanges in digits 2-4, widened phalanges, and shortened and widened metatarsals.",2016-07-07,presents,disease,clinical feature,NGLY1 deficiency,widened phalanges (musculoskeletal abnormalities),1/11,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0001783 ,Q28024539,P1557,Q29647638,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Findings noted only once included flexion deformity of the fingers, hallux valgus, sclerotic lesion of the distal femur, thinning of the fibulas, prominent apophyseal bone formation in the ileac crests and ischia, ulnar bowing, expansion of the cortexes in the proximal and middle phalanges in digits 2-4, widened phalanges, and shortened and widened metatarsals.",2016-07-07,presents,disease,clinical feature,NGLY1 deficiency,shortened and widened metatarsals (musculoskeletal abnormalities),1/11,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0000486,Q28024539,P1557,Q179951,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Our prospective investigations into NGLY1-CDDG revealed several new discoveries associated with this disorder.(...). We also confirmed and further detailed the global developmental delay, movement disorder, frequent seizure disorder, hypotonia, hypolacrima or alacrima, corneal disease, ptosis, lagophthalmous, strabismus, peripheral neuropathy and occasional diminished reflexes, hypohidrosis, auditory brainstem response abnormalities, abnormal brain imaging, scoliosis, acquired microcephaly, small hands and feet, dysmorphic features, constipation, elevated liver enzymes present only early in childhood, osteopenia, and hypocholesterolemia associated with NGLY1-CDDG. ",2016-07-07,presents,disease,phenotype,NGLY1 deficiency,strabismus,discussion,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0001265 ,Q28024539,P1557,Q1419356,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Our prospective investigations into NGLY1-CDDG revealed several new discoveries associated with this disorder.(...). We also confirmed and further detailed the global developmental delay, movement disorder, frequent seizure disorder, hypotonia, hypolacrima or alacrima, corneal disease, ptosis, lagophthalmous, strabismus, peripheral neuropathy and occasional diminished reflexes, hypohidrosis, auditory brainstem response abnormalities, abnormal brain imaging, scoliosis, acquired microcephaly, small hands and feet, dysmorphic features, constipation, elevated liver enzymes present only early in childhood, osteopenia, and hypocholesterolemia associated with NGLY1-CDDG. ",2016-07-07,presents,disease,phenotype,NGLY1 deficiency,occasional diminished reflexes,discussion,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0000966 ,Q28024539,P1557,Q18554019,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Our prospective investigations into NGLY1-CDDG revealed several new discoveries associated with this disorder.(...). We also confirmed and further detailed the global developmental delay, movement disorder, frequent seizure disorder, hypotonia, hypolacrima or alacrima, corneal disease, ptosis, lagophthalmous, strabismus, peripheral neuropathy and occasional diminished reflexes, hypohidrosis, auditory brainstem response abnormalities, abnormal brain imaging, scoliosis, acquired microcephaly, small hands and feet, dysmorphic features, constipation, elevated liver enzymes present only early in childhood, osteopenia, and hypocholesterolemia associated with NGLY1-CDDG. ",2016-07-07,presents,disease,phenotype,NGLY1 deficiency,hypohidrosis,discussion,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0012638,Q28024539,P1557,Q29019857,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Our prospective investigations into NGLY1-CDDG revealed several new discoveries associated with this disorder.(...). We also confirmed and further detailed the global developmental delay, movement disorder, frequent seizure disorder, hypotonia, hypolacrima or alacrima, corneal disease, ptosis, lagophthalmous, strabismus, peripheral neuropathy and occasional diminished reflexes, hypohidrosis, auditory brainstem response abnormalities, abnormal brain imaging, scoliosis, acquired microcephaly, small hands and feet, dysmorphic features, constipation, elevated liver enzymes present only early in childhood, osteopenia, and hypocholesterolemia associated with NGLY1-CDDG. ",2016-07-07,presents,disease,phenotype,NGLY1 deficiency,abnormal brain imaging,discussion,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0200055,Q28024539,P1557,Q29019862,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Our prospective investigations into NGLY1-CDDG revealed several new discoveries associated with this disorder.(...). We also confirmed and further detailed the global developmental delay, movement disorder, frequent seizure disorder, hypotonia, hypolacrima or alacrima, corneal disease, ptosis, lagophthalmous, strabismus, peripheral neuropathy and occasional diminished reflexes, hypohidrosis, auditory brainstem response abnormalities, abnormal brain imaging, scoliosis, acquired microcephaly, small hands and feet, dysmorphic features, constipation, elevated liver enzymes present only early in childhood, osteopenia, and hypocholesterolemia associated with NGLY1-CDDG. ",2016-07-07,presents,disease,phenotype,NGLY1 deficiency,small hands ,discussion,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0001252,Q28024539,P1557,Q1753547,https://www.ncbi.nlm.nih.gov/pubmed/27388694,"Our prospective investigations into NGLY1-CDDG revealed several new discoveries associated with this disorder.(...). We also confirmed and further detailed the global developmental delay, movement disorder, frequent seizure disorder, hypotonia, hypolacrima or alacrima, corneal disease, ptosis, lagophthalmous, strabismus, peripheral neuropathy and occasional diminished reflexes, hypohidrosis, auditory brainstem response abnormalities, abnormal brain imaging, scoliosis, acquired microcephaly, small hands and feet, dysmorphic features, constipation, elevated liver enzymes present only early in childhood, osteopenia, and hypocholesterolemia associated with NGLY1-CDDG. ",2016-07-07,presents,disease,phenotype,NGLY1 deficiency,hypotonia,discussion,NA,2017-04-11,http://orcid.org/0000-0003-0169-8159,NA
UniProt:Q96IV0,skos:exactMatch,exact match,NA,NA,EC:3.5.1.52,Q21119040,P2888,Q21119040,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"The enzyme N-glycanase 1 (NGLY1), also known as peptide:N-glycanase (PNGase, EC 3.5.1.52), catalyzes protein deglycosilation by cleaving the beta-aspartyl glycosylamine bond of N-linked glycoproteins with the subsequent release of intact N-glycan species.",2014-03-20,same_as,protein,enzyme,N-Glycanase 1,PNGase|peptide:N-glycanase,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
UniProt:Q96IV0,RO:0002331,involved in,NA,NA,GO:0006517,Q21119040,P682,Q14905965,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"The enzyme N-glycanase 1 (NGLY1), also known as peptide:N-glycanase (PNGase, EC 3.5.1.52), catalyzes protein deglycosilation by cleaving the beta-aspartyl glycosylamine bond of N-linked glycoproteins with the subsequent release of intact N-glycan species.",2014-03-20,participates,protein,biological process,N-Glycanase 1,protein deglycosilation,NA,GOA (human),2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
UniProt:Q96IV0,RO:0002331,involved in,NA,NA,GO:0006515,Q21119040,P682,Q21108009,https://www.ncbi.nlm.nih.gov/pubmed/24651605,Misfolded glycoproteins are detected by ER luminal lectins and are then translocated to the cytosol via the ERAD machinery to be subsequently degraded by cytosolic enzymes including NGLY1.,2014-03-20,participates,protein,biological process,N-Glycanase 1,misfolded or incompletely synthesized protein catabolic process,NA,GOA (human),2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
UniProt:Q96IV0,RO:0002331,involved in,NA,NA,GO:0006516,Q21119040,P682,Q21101373,https://www.ncbi.nlm.nih.gov/pubmed/24651605,Misfolded glycoproteins are detected by ER luminal lectins and are then translocated to the cytosol via the ERAD machinery to be subsequently degraded by cytosolic enzymes including NGLY1.,2014-03-20,participates,protein,biological process,N-Glycanase 1,glycoprotein catabolic process,NA,GOA (human),2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
UniProt:Q96IV0,RO:0002331,involved in,NA,NA,GO:0097466,Q21119040,P682,Q21115846,https://www.ncbi.nlm.nih.gov/pubmed/24651605,Evidence suggests that NGLY1 participates as a key cytoplasmic component of the endoplasmic reticulum-associated degradation (ERAD) machinery along with the AAA ATPase complex p97. The ERAD pathway is a mechanism for identifying and degrading misfolded glycoproteins.,2014-03-20,participates,protein,biological process,N-Glycanase 1,ubiquitin-dependent glycoprotein ERAD pathway,NA,"Not in GOA, but evidence on Reactome (http://www.reactome.org/content/detail/R-HSA-8850594) [accessed at 2017-03-16]; PMID: 11562482",2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
UniProt:Q96IV0,RO:0002331,involved in,NA,NA,GO:0071712,Q21119040,P682,Q21109270,https://www.ncbi.nlm.nih.gov/pubmed/24651605,Evidence suggests that NGLY1 participates as a key cytoplasmic component of the endoplasmic reticulum-associated degradation (ERAD) machinery along with the AAA ATPase complex p97. The ERAD pathway is a mechanism for identifying and degrading misfolded glycoproteins.,2014-03-20,participates,protein,biological process,N-Glycanase 1,ER-associated misfolded protein catabolic process,NA,Not in GOA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
UniProt:Q96IV0,RO:0002331,involved in,NA,NA,Reactome:R-HSA-532668,Q21119040,P361,Q29017194,https://www.ncbi.nlm.nih.gov/pubmed/24651605,Evidence suggests that NGLY1 participates as a key cytoplasmic component of the endoplasmic reticulum-associated degradation (ERAD) machinery along with the AAA ATPase complex p97. The ERAD pathway is a mechanism for identifying and degrading misfolded glycoproteins.,2014-03-20,participates,protein,pathway,N-Glycanase 1,ERAD pathway,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,note-2017-07-05: ERAD pathway in wikidata as GO term (biological process): https://www.wikidata.org/wiki/Q21101062 (GO:0036503)
UniProt:Q96IV0,RO:0002327,enables,NA,NA,GO:0000224,Q21119040,P680,Q21119039,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"The enzyme N-glycanase 1 (NGLY1), also known as peptide:N-glycanase (PNGase, EC 3.5.1.52), catalyzes protein deglycosilation by cleaving the beta-aspartyl glycosylamine bond of N-linked glycoproteins with the subsequent release of intact N-glycan species.",2014-03-20,molecular_activity,protein,molecular function,N-Glycanase 1,"cleavage of the B-aspartyl glycosylamine bond of N-linked glycoproteins, releasing intact N-glycans from proteins bound for degradation.",NA,GOA (human),2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
UniProt:Q96IV0,RO:0002331,involved in,NA,NA,Reactome:R-HSA-8850594,Q21119040,P361,Q29017200,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"The enzyme N-glycanase 1 (NGLY1), also known as peptide:N-glycanase (PNGase, EC 3.5.1.52), catalyzes protein deglycosilation by cleaving the beta-aspartyl glycosylamine bond of N-linked glycoproteins with the subsequent release of intact N-glycan species.",2014-03-20,participates,protein,reaction,N-Glycanase 1,Deglycosylation complex hydrolyses N-glycans from unfolded glycoproteins,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
UniProt:Q96IV0,BFO:0000050,is part of,NA,NA,GO:0005829,Q21119040,P681,Q220599,https://www.ncbi.nlm.nih.gov/pubmed/24651605,Misfolded glycoproteins are detected by ER luminal lectins and are then translocated to the cytosol via the ERAD machinery to be subsequently degraded by cytosolic enzymes including NGLY1.,2014-03-20,in_cell_component,protein,cell component,N-Glycanase 1,cytosol,NA,GOA (human),2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
UniProt:Q96IV0,BFO:0000050,is part of,NA,NA,GO:0005737,Q21119040,P681,Q79899,https://www.ncbi.nlm.nih.gov/pubmed/24651605,Evidence suggests that NGLY1 participates as a key cytoplasmic component of the endoplasmic reticulum-associated degradation (ERAD) machinery along with the AAA ATPase complex p97.,2014-03-20,in_cell_component,protein,cell component,N-Glycanase 1,cytoplasm,NA,GOA (human),2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
Reactome:R-HSA-8850594,RO:0002331,involved in,NA,NA,Reactome:R-HSA-532668,Q29017200,P361,Q29017194,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"The enzyme N-glycanase 1 (NGLY1), also known as peptide:N-glycanase (PNGase, EC 3.5.1.52), catalyzes protein deglycosilation by cleaving the beta-aspartyl glycosylamine bond of N-linked glycoproteins with the subsequent release of intact N-glycan species.(...).Evidence suggests that NGLY1 participates as a key cytoplasmic component of the endoplasmic reticulum-associated degradation (ERAD) machinery along with the AAA ATPase complex p97. The ERAD pathway is a mechanism for identifying and degrading misfolded glycoproteins.",2014-03-20,participates,reaction ,pathway,Deglycosylation complex hydrolyses N-glycans from unfolded glycoproteins,ERAD pathway,NA,http://www.reactome.org/content/detail/R-HSA-532668,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
Reactome:R-HSA-8850590,RO:0002327,enables,NA,NA,Reactome:R-HSA-8850594,Q29017196,P128,Q29017200,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"The enzyme N-glycanase 1 (NGLY1), also known as peptide:N-glycanase (PNGase, EC 3.5.1.52), catalyzes protein deglycosilation by cleaving the beta-aspartyl glycosylamine bond of N-linked glycoproteins with the subsequent release of intact N-glycan species.(...). Evidence suggests that NGLY1 participates as a key cytoplasmic component of the endoplasmic reticulum-associated degradation (ERAD) machinery along with the AAA ATPase complex p97.",2014-03-20,regulates,protein complex,reaction,Deglycosylation complex|ERAD machinery|AAA ATPase complex p97,Deglycosylation complex hydrolyses N-glycans from unfolded glycoproteins,NA,http://www.reactome.org/content/detail/R-HSA-8850594,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
UniProt:Q96IV0,BFO:0000050,is part of,NA,NA,Reactome:R-HSA-8850590,Q21119040,P361,Q29017196,https://www.ncbi.nlm.nih.gov/pubmed/24651605,Evidence suggests that NGLY1 participates as a key cytoplasmic component of the endoplasmic reticulum-associated degradation (ERAD) machinery along with the AAA ATPase complex p97.,2014-03-20,is_component_of,protein,protein complex,N-Glycanase 1,Deglycosylation complex|ERAD machinery|AAA ATPase complex p97,NA,http://www.reactome.org/content/detail/R-HSA-8850590,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
UniProt:P55072,BFO:0000050,is part of,NA,NA,Reactome:R-HSA-8850590,Q21109279,P361,Q29017196,https://www.ncbi.nlm.nih.gov/pubmed/24651605,Evidence suggests that NGLY1 participates as a key cytoplasmic component of the endoplasmic reticulum-associated degradation (ERAD) machinery along with the AAA ATPase complex p97.,2014-03-20,is_component_of,protein,protein complex,Transitional endoplasmic reticulum ATPase|AAA ATPase p97,Deglycosylation complex|ERAD machinery|AAA ATPase complex p97,NA,http://www.sciencedirect.com/science/article/pii/S109727650000143X;http://www.reactome.org/content/detail/R-HSA-8850590,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
UniProt:Q96IV0,RO:0002434,interacts with,NA,NA,UniProt:P55072,Q21119040,P129,Q21109279,https://www.ncbi.nlm.nih.gov/pubmed/24651605,Evidence suggests that NGLY1 participates as a key cytoplasmic component of the endoplasmic reticulum-associated degradation (ERAD) machinery along with the AAA ATPase complex p97.,2014-03-20,interacts,protein,protein,N-Glycanase 1,Transitional endoplasmic reticulum ATPase|AAA ATPase p97,NA,https://thebiogrid.org/120885/summary/homo-sapiens/ngly1.html,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
NCBIGene:55768,RO:0002434,interacts with,NA,NA,NCBIGene:7415,Q18042037,P129,Q18032318,https://www.ncbi.nlm.nih.gov/pubmed/24651605,Evidence suggests that NGLY1 participates as a key cytoplasmic component of the endoplasmic reticulum-associated degradation (ERAD) machinery along with the AAA ATPase complex p97.,2014-03-20,interacts,gene,gene,NGLY1,VCP|p97,NA,https://thebiogrid.org/120885/summary/homo-sapiens/ngly1.html,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,skos:exactMatch,exact match,NA,NA,OMIM:615273,Q28024539,P2888,Q28024539,https://www.ncbi.nlm.nih.gov/pubmed/24651605,The finding of compound heterozygous loss of function mutations in NGLY1 in the original case suggested that NGLY1 deficiency (OMIM 615273) represents a new disorder.,2014-03-20,same_as,disease,disease,NGLY1 deficiency,NGLY1 deficiency,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,SIO:000008,has attribute,NA,NA,HP:0000007,Q28024539,P1552,Q15729064,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"NGLY1 deficiency is a novel autosomal recessive disorder of the endoplasmic reticulum-associated degradation pathway associated with neurological dysfunction, abnormal tear production, and liver disease.",2014-03-20,has_attribute,disease,mode of inheritance,NGLY1 deficiency,autosomal recessive disorder,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
Reactome:R-HSA-532668,RO:0002200,has phenotype,NA,NA,DOID:0060728,Q29017194,P2293,Q28024539,https://www.ncbi.nlm.nih.gov/pubmed/24651605,These observations confirm NGLY1 deficiency as an inherited disorder associated with the ERAD process and document its clinical presentation.,2014-03-20,associates,pathway,disease,ERAD pathway,NGLY1 deficiency,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
UniProt:Q96IV0,RO:0002200,has phenotype,NA,NA,DOID:0060728,Q21119040,P2293,Q28024539,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"To define the phenotype associated with a novel inherited disorder of cytosolic endoplasmic reticulum-associated degradation pathway dysfunction, we studied a series of eight patients with deficiency of N-glycanase 1.",2014-03-20,associates,protein,disease,N-Glycanase 1,NGLY1 deficiency,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
NCBIGene:55768,RO:0002200,has phenotype,NA,NA,DOID:0060728,Q18042037,P2293,Q28024539,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"To date, a single patient with NGLY1 deficiency has been reported as part of a whole-exome sequencing (WES) study focusing on the utility of this technology to detect  the underlying genetic etiology of disorders affecting patients with previously undiagnosed or unresolved genetic conditions. Neet et al. described a 3-year-old boy with compound heterozygous inactivating mutations in NGLY1 and suggested that this could be a new disorder. ",2014-03-20,associates,gene,disease,NGLY1,NGLY1 deficiency,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
NCBIGene:55768,RO:0002205,has gene product,NA,NA,UniProt:Q96IV0,Q18042037,P688,Q21119040,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"Misfolded glycoproteins are detected by ER luminal lectins and are then translocated to the cytosol via the ERAD machinery to be subsequently degraded by cytosolic enzymes including NGLY1. To date, a single patient with NGLY1 deficiency has been reported as part of a whole-exome sequencing (WES) study focusing on the utility of this technology to detect  the underlying genetic etiology of disorders affecting patients with previously undiagnosed or unresolved genetic conditions. Neet et al. described a 3-year-old boy with compound heterozygous inactivating mutations in NGLY1 and suggested that this could be a new disorder. ",2014-03-20,encodes,gene,protein,NGLY1 gene,N-Glycanase 1,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,PATO:0001668,associated with,NA,NA,SO:0001587,Q28024539,P2293,Q28371788,https://www.ncbi.nlm.nih.gov/pubmed/24651605,The finding of compound heterozygous loss of function mutations in NGLY1 in the original case suggested that NGLY1 deficiency (OMIM 615273) represents a new disorder.,2014-03-20,associates,disease,variant class,NGLY1 deficiency,nonsense mutation|loss of function mutation|inactivating mutation|stop-gain mutation,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
HGVS:NM_018297.3:c.1201A>T,RO:0002200,has phenotype,NA,NA,DOID:0060728,Q29016913,P2293,Q28024539,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"The nonsense mutation c.1201A>T (p.R401X) was the most commonly detected deleterious allele in NGLY1, present in homozygous state in five of eight cases (Patients 4-8) and in a compound heterozygous state in one case (Patient 1). Clearly, homozygous mutations associated with p.R401X cause a severe phenotype. However, the range of outcomes is variable, with some patients having an early demise and others living at least into their teenage years. Patients 2 and 3 appear to have a relatively mild phenotype and are the only two individuals in the current cohort who do not carry the p.R401X mutation. Aside from these broad considerations, more detailed genotype-phenotype correlations will be possible only with the detection of further patients. Consistent with the severe presentation of NGLY1 deficiency, NGLY1 is among the 20% of genes in the human genome that are the most intolerant of functional genetic variation in the human population, and we may expect that less extreme mutations than those seen here may also be associated with disease.",2014-03-20,associates,variant,disease,c.1201A>T (p.R401X),NGLY1 deficiency,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
HGVS:NM_018297.3:c.1201A>T,SIO:000008,has attribute,NA,NA,SO:0001587,Q29016913,P1552,Q28371788,https://www.ncbi.nlm.nih.gov/pubmed/24651605,The nonsense mutation c.1201A>T (p.R401X) was the most common deleterious allele.,2014-03-20,has_attribute,variant,variant class,c.1201A>T (p.R401X),nonsense mutation|loss of function mutation|inactivating mutation|stop-gain mutation,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
HGVS:NM_018297.3:c.1201A>T,GENO:0000418,has affected feature,NA,NA,NCBIGene:55768,Q29016913,P3433,Q18042037,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"The nonsense mutation c.1201A>T (p.R401X) was the most commonly detected deleterious allele in NGLY1, present in homozygous state in five of eight cases (Patients 4-8) and in a compound heterozygous state in one case (Patient 1).",2014-03-20,in_gene,variant,gene,c.1201A>T (p.R401X),NGLY1,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
SO:0001587,GENO:0000418,has affected feature,NA,NA,NCBIGene:55768,Q28371788,P3433,Q18042037,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"The nonsense mutation c.1201A>T (p.R401X) was the most commonly detected deleterious allele in NGLY1, present in homozygous state in five of eight cases (Patients 4-8) and in a compound heterozygous state in one case (Patient 1).",2014-03-20,in_gene,variant class,gene,nonsense mutation|loss of function mutation|inactivating mutation|stop-gain mutation,NGLY1,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
GO:0006517,RO:0002200,has phenotype,NA,NA,DOID:0060728,Q14905965,P2293,Q28024539,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"On the basis of the initial report of a single NGLY1-deficient patient, a recent CDG review considered that NGLY1 deficiency may even be considered to be the first ""congenital disorder of deglycosylation"".",2014-03-20,associates,biological process,disease,deglycosilation,NGLY1 deficiency,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
GO:0000502,RO:0002200,has phenotype,NA,NA,DOID:0060728,Q14878333,P2293,Q28024539,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"Soon after the initial report, we were able to identify the seven additional cases reported herein, therefore confirming NGLY1 deficiency as an inherited disorder of the ERAD pathway and the first to be identified that involves the cytosolic proteasome.",2014-03-20,associates,protein complex,disease,proteasome,NGLY1 deficiency,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
MESH:D006023,RO:0002331,involved in,NA,NA,Reactome:R-HSA-532668,Q29017226,P361,Q29017194,https://www.ncbi.nlm.nih.gov/pubmed/24651605,The ERAD pathway is a mechanism for identifying and degrading misfolded glycoproteins.,2014-03-20,participates,protein,pathway,misfolded glycoprotein,ERAD pathway,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
MESH:D006023,RO:0002331,involved in,NA,NA,MESH:D055571,Q29017226,P361,Q7444453,https://www.ncbi.nlm.nih.gov/pubmed/24651605,The ERAD pathway is a mechanism for identifying and degrading misfolded glycoproteins. N-glycans that are high in mannose content act as quality control tags for proteins in the early stages of the secretory pathway. Misfolded glycoproteins are detected by ER luminal lectins and are then translocated to the cytosol via the ERAD machinery to be subsequently degraded by cytosolic enzymes including NGLY1.,2014-03-20,participates,protein,pathway,misfolded glycoprotein,Secretory pathway,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
MESH:D006023,RO:0002434,interacts with,NA,NA,UMLS:C0023206,Q29017226,P129,Q408693,https://www.ncbi.nlm.nih.gov/pubmed/24651605,Misfolded glycoproteins are detected by ER luminal lectins and are then translocated to the cytosol via the ERAD machinery to be subsequently degraded by cytosolic enzymes including NGLY1.,2014-03-20,interacts,protein,protein,misfolded glycoprotein,ER luminal lectins,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
DOID:0050602,SIO:000008,has attribute,NA,NA,HP:0000007,Q7843329,P1552,Q15729064,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"Triple-A syndrome (OMIM 231550) is an autosomal recessive condition characterized by adrenocorticotropin hormone-resistant adrenal insufficiency, achalasia, and alacrima.",2014-03-20,has_attribute,disease,mode of inheritance,Triple-A syndrome,autosomal recessive disorder,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
DOID:0050602,skos:exactMatch,exact match,NA,NA,OMIM:231550,Q7843329,P2888,Q7843329,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"Triple-A syndrome (OMIM 231550) is an autosomal recessive condition characterized by adrenocorticotropin hormone-resistant adrenal insufficiency, achalasia, and alacrima.",2014-03-20,same_as,disease,disease,Triple-A syndrome,Triple-A syndrome,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
DOID:0050602,RO:0002200,has phenotype,NA,NA,HP:0008259,Q7843329,P1557,Q29019846,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"Triple-A syndrome (OMIM 231550) is an autosomal recessive condition characterized by adrenocorticotropin hormone-resistant adrenal insufficiency, achalasia, and alacrima.",2014-03-20,presents,disease,phenotype,Triple-A syndrome,adrenocorticotropin hormone-resistant adrenal insufficiency,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
DOID:0050602,RO:0002200,has phenotype,NA,NA,HP:0002571,Q7843329,P1557,Q661015,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"Triple-A syndrome (OMIM 231550) is an autosomal recessive condition characterized by adrenocorticotropin hormone-resistant adrenal insufficiency, achalasia, and alacrima.",2014-03-20,presents,disease,phenotype,Triple-A syndrome,achalasia,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
DOID:0050602,RO:0002200,has phenotype,NA,NA,HP:0000522,Q7843329,P1557,Q19595845,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"Triple-A syndrome (OMIM 231550) is an autosomal recessive condition characterized by adrenocorticotropin hormone-resistant adrenal insufficiency, achalasia, and alacrima.",2014-03-20,presents,disease,phenotype,Triple-A syndrome,alacrima,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
DOID:0050602,RO:0002200,has phenotype,NA,NA,HP:0001251,Q7843329,P1557,Q154709,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"Triple-A syndrome (OMIM 231550) is an autosomal recessive condition characterized by adrenocorticotropin hormone-resistant adrenal insufficiency, achalasia, and alacrima. In addition, affected individuals have late-onset cerebellar ataxia, peripheral neuropathy, and mild dementia.",2014-03-20,presents,disease,phenotype,Triple-A syndrome,late-onset cerebellar ataxia,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
DOID:0050602,RO:0002200,has phenotype,NA,NA,HP:0009830,Q7843329,P1557,Q18556979,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"Triple-A syndrome (OMIM 231550) is an autosomal recessive condition characterized by adrenocorticotropin hormone-resistant adrenal insufficiency, achalasia, and alacrima. In addition, affected individuals have late-onset cerebellar ataxia, peripheral neuropathy, and mild dementia.",2014-03-20,presents,disease,phenotype,Triple-A syndrome,peripheral neuropathy,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
DOID:0050602,RO:0002200,has phenotype,NA,NA,HP:0000726,Q7843329,P1557,Q83030,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"Triple-A syndrome (OMIM 231550) is an autosomal recessive condition characterized by adrenocorticotropin hormone-resistant adrenal insufficiency, achalasia, and alacrima. In addition, affected individuals have late-onset cerebellar ataxia, peripheral neuropathy, and mild dementia.",2014-03-20,presents,disease,phenotype,Triple-A syndrome,mild dementia,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
UniProt:Q9NRG9,RO:0002200,has phenotype,NA,NA,DOID:0050602,Q4649718,P2293,Q7843329,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"Aladin, the gene product of triple-A syndrome, is a member of the WD-repeat family of regulatory proteins, with ubiquitous expression in human tissues but with particularly abundant expression in the cerebellum, adrenal and pituitary glands, and gastrointestinal structures.",2014-03-20,associates,protein,disease,Aladin,Triple-A syndrome,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
NCBIGene:8086,RO:0002200,has phenotype,NA,NA,DOID:0050602,Q18032728,P2293,Q7843329,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"Aladin, the gene product of triple-A syndrome, is a member of the WD-repeat family of regulatory proteins, with ubiquitous expression in human tissues but with particularly abundant expression in the cerebellum, adrenal and pituitary glands, and gastrointestinal structures.",2014-03-20,associates,gene,disease,AAAS aladin WD repeat nucleoporin,Triple-A syndrome,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
NCBIGene:8086,RO:0002205,has gene product,NA,NA,UniProt:Q9NRG9,Q18032728,P688,Q4649718,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"Aladin, the gene product of triple-A syndrome, is a member of the WD-repeat family of regulatory proteins, with ubiquitous expression in human tissues but with particularly abundant expression in the cerebellum, adrenal and pituitary glands, and gastrointestinal structures.",2014-03-20,encodes,gene,protein,AAAS aladin WD repeat nucleoporin,Aladin,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
InterPro:IPR001680,BFO:0000050,is part of,NA,NA,UniProt:Q9NRG9,Q7948257,P361,Q4649718,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"Aladin, the gene product of triple-A syndrome, is a member of the WD-repeat family of regulatory proteins, with ubiquitous expression in human tissues but with particularly abundant expression in the cerebellum, adrenal and pituitary glands, and gastrointestinal structures.",2014-03-20,is_component_of,structural motif,protein,WD40 repeat,Aladin,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,i couldn't put <protein is instance of protein class (WD repeat protein family [https://www.genenames.org/cgi-bin/genefamilies/set/362])> because i couldn't find this protein class term in any ontology.. 
UniProt:Q9NRG9,RO:0002206,expressed in,NA,NA,UBERON:0002037,Q4649718,P2293,Q130983,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"Aladin, the gene product of triple-A syndrome, is a member of the WD-repeat family of regulatory proteins, with ubiquitous expression in human tissues but with particularly abundant expression in the cerebellum, adrenal and pituitary glands, and gastrointestinal structures.",2014-03-20,abundant_protein_expression_in,protein,anatomy,Aladin,cerebellum,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
UniProt:Q9NRG9,RO:0002206,expressed in,NA,NA,UBERON:0002369,Q4649718,P2293,Q712294,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"Aladin, the gene product of triple-A syndrome, is a member of the WD-repeat family of regulatory proteins, with ubiquitous expression in human tissues but with particularly abundant expression in the cerebellum, adrenal and pituitary glands, and gastrointestinal structures.",2014-03-20,abundant_protein_expression_in,protein,anatomy,Aladin,adrenal gland,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
UniProt:Q9NRG9,RO:0002206,expressed in,NA,NA,UBERON:0000007,Q4649718,P2293,Q156871,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"Aladin, the gene product of triple-A syndrome, is a member of the WD-repeat family of regulatory proteins, with ubiquitous expression in human tissues but with particularly abundant expression in the cerebellum, adrenal and pituitary glands, and gastrointestinal structures.",2014-03-20,abundant_protein_expression_in,protein,anatomy,Aladin,pituitary gland,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
UniProt:Q9NRG9,RO:0002206,expressed in,NA,NA,UBERON:0001007,Q4649718,P2293,Q9649,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"Aladin, the gene product of triple-A syndrome, is a member of the WD-repeat family of regulatory proteins, with ubiquitous expression in human tissues but with particularly abundant expression in the cerebellum, adrenal and pituitary glands, and gastrointestinal structures.",2014-03-20,abundant_protein_expression_in,protein,anatomy,Aladin,gastrointestinal structures/tissues,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
Orphanet:869,SIO:000008,has attribute,NA,NA,HP:0000007,Q7843329,P1552,Q15729064,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"Alacrima, achalasia, and mental retardation syndrome (OMIM 615510) is another autosomal recessive condition that features alacrima and neurological involvement, but adrenal fundtion is normal.",2014-03-20,has_attribute,disease,mode of inheritance,"Alacrima, achalasia, and mental retardation syndrome",autosomal recessive disorder,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
Orphanet:869,skos:exactMatch,exact match,NA,NA,OMIM:615510,Q7843329,P2888,Q29017164,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"Alacrima, achalasia, and mental retardation syndrome (OMIM 615510) is another autosomal recessive condition that features alacrima and neurological involvement, but adrenal fundtion is normal.",2014-03-20,same_as,disease,disease,"Alacrima, achalasia, and mental retardation syndrome","Alacrima, achalasia, and mental retardation syndrome",NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
Orphanet:869,RO:0002200,has phenotype,NA,NA,HP:0000522,Q7843329,P1557,Q19595845,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"Alacrima, achalasia, and mental retardation syndrome (OMIM 615510) is another autosomal recessive condition that features alacrima and neurological involvement, but adrenal fundtion is normal.",2014-03-20,presents,disease,phenotype,"Alacrima, achalasia, and mental retardation syndrome",alacrima,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
Orphanet:869,RO:0002200,has phenotype,NA,NA,HP:0002571,Q7843329,P1557,Q661015,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"Alacrima, achalasia, and mental retardation syndrome (OMIM 615510) is another autosomal recessive condition that features alacrima and neurological involvement, but adrenal fundtion is normal.(...). In addition to the primary clinical findings delineated in its name, alacrima, achalasia, and  mental retardation patients have variable hypotonia, ataxia, spasticity, and hearing impairment.",2014-03-20,presents,disease,phenotype,"Alacrima, achalasia, and mental retardation syndrome",achalasia,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
Orphanet:869,RO:0002200,has phenotype,NA,NA,HP:0001263,Q7843329,P1557,Q1142806,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"Alacrima, achalasia, and mental retardation syndrome (OMIM 615510) is another autosomal recessive condition that features alacrima and neurological involvement, but adrenal fundtion is normal.(...). In addition to the primary clinical findings delineated in its name, alacrima, achalasia, and  mental retardation patients have variable hypotonia, ataxia, spasticity, and hearing impairment.",2014-03-20,presents,disease,phenotype,"Alacrima, achalasia, and mental retardation syndrome",mental retardation,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
Orphanet:869,RO:0002200,has phenotype,NA,NA,HP:0001252,Q7843329,P1557,Q1753547,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"Alacrima, achalasia, and mental retardation syndrome (OMIM 615510) is another autosomal recessive condition that features alacrima and neurological involvement, but adrenal fundtion is normal.(...). In addition to the primary clinical findings delineated in its name, alacrima, achalasia, and  mental retardation patients have variable hypotonia, ataxia, spasticity, and hearing impairment.",2014-03-20,presents,disease,phenotype,"Alacrima, achalasia, and mental retardation syndrome",hypotonia,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
Orphanet:869,RO:0002200,has phenotype,NA,NA,HP:0001251,Q7843329,P1557,Q154709,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"Alacrima, achalasia, and mental retardation syndrome (OMIM 615510) is another autosomal recessive condition that features alacrima and neurological involvement, but adrenal fundtion is normal.(...). In addition to the primary clinical findings delineated in its name, alacrima, achalasia, and  mental retardation patients have variable hypotonia, ataxia, spasticity, and hearing impairment.",2014-03-20,presents,disease,phenotype,"Alacrima, achalasia, and mental retardation syndrome",ataxia,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
Orphanet:869,RO:0002200,has phenotype,NA,NA,HP:0001257,Q7843329,P1557,Q117060,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"Alacrima, achalasia, and mental retardation syndrome (OMIM 615510) is another autosomal recessive condition that features alacrima and neurological involvement, but adrenal fundtion is normal.(...). In addition to the primary clinical findings delineated in its name, alacrima, achalasia, and  mental retardation patients have variable hypotonia, ataxia, spasticity, and hearing impairment.",2014-03-20,presents,disease,phenotype,"Alacrima, achalasia, and mental retardation syndrome",spasticity,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
Orphanet:869,RO:0002200,has phenotype,NA,NA,HP:0000365,Q7843329,P1557,Q12133,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"Alacrima, achalasia, and mental retardation syndrome (OMIM 615510) is another autosomal recessive condition that features alacrima and neurological involvement, but adrenal fundtion is normal.(...). In addition to the primary clinical findings delineated in its name, alacrima, achalasia, and  mental retardation patients have variable hypotonia, ataxia, spasticity, and hearing impairment.",2014-03-20,presents,disease,phenotype,"Alacrima, achalasia, and mental retardation syndrome",hearing impairment,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
NCBIGene:29926,RO:0002200,has phenotype,NA,NA,Orphanet:869,Q18039700,P2293,Q7843329,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"Alacrima, achalasia, and mental retardation syndrome is caused by mutations in GMPPA, a gene that encodes guanosine diphosphate-mannose pyrophosphorylase A (GMPPA). ",2014-03-20,associates,gene,disease,GMPPA,"Alacrima, achalasia, and mental retardation syndrome",NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
NCBIGene:29926,RO:0002205,has gene product,NA,NA,UniProt:Q96IJ6,Q18039700,P688,Q21112873,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"Alacrima, achalasia, and mental retardation syndrome is caused by mutations in GMPPA, a gene that encodes guanosine diphosphate-mannose pyrophosphorylase A (GMPPA). ",2014-03-20,encodes,gene,protein,GMPPA,guanosine diphosphate-mannose pyrophosphorylase A (GMPPA),NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
NCBIGene:29926,RO:0002434,interacts with,NA,NA,NCBIGene:29925,Q18039700,P129,Q18039699,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"GMPPA appears to be a regulatory subunit to GMPPB, an enzyme that catalyzes the formation of guanosine diphosphate mannose.",2014-03-20,interacts,gene,gene,GMPPA,GMPPB,NA,https://thebiogrid.org/118967,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
NCBIGene:29925,RO:0002205,has gene product,NA,NA,UniProt:Q9Y5P6,Q18039699,P688,Q21110385,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"GMPPA appears to be a regulatory subunit to GMPPB, an enzyme that catalyzes the formation of guanosine diphosphate mannose.",2014-03-20,encodes,gene,protein,GMPPB,Mannose-1-phosphate guanyltransferase beta,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
DOID:11589,RO:0002200,has phenotype,NA,NA,HP:0000522,Q2325854,P1557,Q19595845,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"Alacrima has also been described in different forms of hereditary sensory and autonomic neuropathy, including type III (also known as familial disautonomia or Riley-Day syndrome) (OMIM 223900) and type VI (OMIM 614653).",2014-03-20,presents,disease,phenotype,Riley-Day syndrome,alacrima,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
Orphanet:314381,RO:0002200,has phenotype,NA,NA,HP:0000522,Q29017175,P1557,Q19595845,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"Alacrima has also been described in different forms of hereditary sensory and autonomic neuropathy, including type III (also known as familial disautonomia or Riley-Day syndrome) (OMIM 223900) and type VI (OMIM 614653).",2014-03-20,presents,disease,phenotype,Hereditary sensory and autonomic neuropathy type 6,alacrima,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
DOID:11589,skos:exactMatch,exact match,NA,NA,OMIM:223900,Q2325854,P2888,Q2325854,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"Alacrima has also been described in different forms of hereditary sensory and autonomic neuropathy, including type III (also known as familial disautonomia or Riley-Day syndrome) (OMIM 223900) and type VI (OMIM 614653).",2014-03-20,same_as,disease,disease,Riley-Day syndrome,Riley-Day syndrome,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
Orphanet:314381,skos:exactMatch,exact match,NA,NA,OMIM:614653,Q29017175,P2888,Q3702898,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"Alacrima has also been described in different forms of hereditary sensory and autonomic neuropathy, including type III (also known as familial disautonomia or Riley-Day syndrome) (OMIM 223900) and type VI (OMIM 614653).",2014-03-20,same_as,disease,disease,Hereditary sensory and autonomic neuropathy type 6,Hereditary sensory and autonomic neuropathy type 6,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
DOID:5212,RO:0002200,has phenotype,NA,NA,HP:0001511,Q1125675,P1557,Q29019673,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"Although there are clear similarities between NGLY1 deficiency and the CDGs as a whole, such as IUGR, failure to thrive, global developmental delay, and liver impairment, these features are nonspecific.",2014-03-20,presents,disease,phenotype,Congenital disorder of glycosylation|CDG,IUGR,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
DOID:5212,RO:0002200,has phenotype,NA,NA,HP:0001508,Q1125675,P1557,Q1497481,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"Although there are clear similarities between NGLY1 deficiency and the CDGs as a whole, such as IUGR, failure to thrive, global developmental delay, and liver impairment, these features are nonspecific.",2014-03-20,presents,disease,phenotype,Congenital disorder of glycosylation|CDG,failure to thrive,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
DOID:5212,RO:0002200,has phenotype,NA,NA,HP:0001263,Q1125675,P1557,Q1142806,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"Although there are clear similarities between NGLY1 deficiency and the CDGs as a whole, such as IUGR, failure to thrive, global developmental delay, and liver impairment, these features are nonspecific.",2014-03-20,presents,disease,phenotype,Congenital disorder of glycosylation|CDG,global developmental delay,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
DOID:5212,RO:0002200,has phenotype,NA,NA,HP:0001392,Q1125675,P1557,Q29020078,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"Although there are clear similarities between NGLY1 deficiency and the CDGs as a whole, such as IUGR, failure to thrive, global developmental delay, and liver impairment, these features are nonspecific.",2014-03-20,presents,disease,phenotype,Congenital disorder of glycosylation|CDG,liver impairment,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
NCBIGene:11253,RO:0002200,has phenotype,NA,NA,DOID:0060308,Q18036434,P2293,Q19587384,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"Mutations in MAN1B1, the gene coding for alpha-1,2-mannosidase, are associated with nonsyndromic autosomal recessive intellectual disability and subtle dysmorphic features.",2014-03-20,associates,gene,disease,MAN1B1,nonsyndromic autosomal recessive intellectual disability,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
NCBIGene:11253,RO:0002200,has phenotype,NA,NA,HP:0001999 ,Q18036434,P2293,Q29019704,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"Mutations in MAN1B1, the gene coding for alpha-1,2-mannosidase, are associated with nonsyndromic autosomal recessive intellectual disability and subtle dysmorphic features.",2014-03-20,associates,gene,phenotype,MAN1B1,dysmorphic features,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
NCBIGene:11253,RO:0002205,has gene product,NA,NA,UniProt:Q9UKM7,Q18036434,P688,Q21121661,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"Mutations in MAN1B1, the gene coding for alpha-1,2-mannosidase, are associated with nonsyndromic autosomal recessive intellectual disability and subtle dysmorphic features.",2014-03-20,encodes,gene,protein,MAN1B1,"alpha-1,2-mannosidase",NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
UniProt:Q9UKM7,rdf:type,instance of,NA,NA,EDAM:topic_0820,Q21121661,P31,Q29017222,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"alpha-1,2-Mannosidase is a type II transmembrane protein that is primarily localized to the Golgi apparatus, where it undergoes O-glycosylation and participates in glycoprotein quality control.",2014-03-20,instance_of,protein,protein class,"alpha-1,2-mannosidase",type II transmembrane protein,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
UniProt:Q9UKM7,BFO:0000050,is part of,NA,NA,GO:0005794,Q21121661,P681,Q83181,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"alpha-1,2-Mannosidase is a type II transmembrane protein that is primarily localized to the Golgi apparatus, where it undergoes O-glycosylation and participates in glycoprotein quality control.",2014-03-20,in_cell_component,protein,cell component,"alpha-1,2-mannosidase",Golgi apparatus,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
UniProt:Q9UKM7,RO:0002331,involved in,NA,NA,Reactome:R-HSA-532668,Q21121661,P361,Q29017194,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"Recently, disorders associated with components of the ERAD pathway involving the Golgi apparatus, ER lipid raft-associated protein 1/2 (erlin1/2) complex, and E3-ubiquitin ligase have been identified.(...). alpha-1,2-Mannosidase is a type II transmembrane protein that is primarily localized to the Golgi apparatus, where it undergoes O-glycosylation and participates in glycoprotein quality control.",2014-03-20,participates,protein,pathway,"alpha-1,2-mannosidase",ERAD pathway,NA,http://www.uniprot.org/uniprot/Q9UKM7,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
NCBIGene:11160,RO:0002200,has phenotype,NA,NA,HP:0002187,Q18036170,P2293,Q183560,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"Profound intellectual disability, developmental regression, and mutliple contractures are features associated with autosomal recessive mutations in ERLIN2.",2014-03-20,associates,gene,phenotype,ERLIN2,Profound intellectual disability,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
NCBIGene:11160,RO:0002200,has phenotype,NA,NA,HP:0002376,Q18036170,P2293,Q17009018,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"Profound intellectual disability, developmental regression, and mutliple contractures are features associated with autosomal recessive mutations in ERLIN2.",2014-03-20,associates,gene,phenotype,ERLIN2,developmental regression,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
NCBIGene:11160,RO:0002200,has phenotype,NA,NA,HP:0002828,Q18036170,P2293,Q1480291,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"Profound intellectual disability, developmental regression, and mutliple contractures are features associated with autosomal recessive mutations in ERLIN2.",2014-03-20,associates,gene,phenotype,ERLIN2,mutliple contractures,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
NCBIGene:11160,RO:0002200,has phenotype,NA,NA,DOID:2476,Q18036170,P2293,Q657516,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"Another family was found to have a homozygous null mutation in ERLIN2, with affected individuals presenting with a hereditary spastic paraplegia phenotype.",2014-03-20,associates,gene,disease,ERLIN2,hereditary spastic paraplegia,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
NCBIGene:11160,RO:0002331,involved in,NA,NA,Reactome:R-HSA-532668,Q18036170,P361,Q29017194,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"In this case, abnormal erlin2 causes impaired ERAD of activated inositol 1,4,5-triphosphate (IP3) receptors and other substrates by compromising the structure of the erlin1/2 complex.",2014-03-20,participates,gene,pathway,ERLIN2,ERAD pathway,NA,http://www.reactome.org/content/detail/R-HSA-8866531,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
NCBIGene:11160,RO:0002434,interacts with,NA,NA,NCBIGene:10613,Q18036170,P129,Q18035529,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"In this case, abnormal erlin2 causes impaired ERAD of activated inositol 1,4,5-triphosphate (IP3) receptors and other substrates by compromising the structure of the erlin1/2 complex.",2014-03-20,interacts,gene,gene,ERLIN2,ERLIN1,NA,https://thebiogrid.org/116331,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
UniProt:O94905,RO:0002434,interacts with,NA,NA,UniProt:O75477,Q21130396,P129,Q21131645,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"In this case, abnormal erlin2 causes impaired ERAD of activated inositol 1,4,5-triphosphate (IP3) receptors and other substrates by compromising the structure of the erlin1/2 complex.",2014-03-20,interacts,protein,protein,ER lipid raft associated 2,ER lipid raft associated 1,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
UniProt:O94905,BFO:0000050,is part of,NA,NA,Reactome:R-HSA-8866522,Q21130396,P361,Q29017201,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"In this case, abnormal erlin2 causes impaired ERAD of activated inositol 1,4,5-triphosphate (IP3) receptors and other substrates by compromising the structure of the erlin1/2 complex.",2014-03-20,is_component_of,protein,protein complex,ER lipid raft associated 2,erlin1/2 complex,NA,http://www.reactome.org/content/detail/R-HSA-8866522,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
UniProt:O75477,BFO:0000050,is part of,NA,NA,Reactome:R-HSA-8866522,Q21131645,P361,Q29017201,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"In this case, abnormal erlin2 causes impaired ERAD of activated inositol 1,4,5-triphosphate (IP3) receptors and other substrates by compromising the structure of the erlin1/2 complex.",2014-03-20,is_component_of,protein,protein complex,ER lipid raft associated 1,erlin1/2 complex,NA,http://www.reactome.org/content/detail/R-HSA-8866522,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
NCBIGene:11160,RO:0002205,has gene product,NA,NA,UniProt:O94905,Q18036170,P688,Q21130396,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"In this case, abnormal erlin2 causes impaired ERAD of activated inositol 1,4,5-triphosphate (IP3) receptors and other substrates by compromising the structure of the erlin1/2 complex.",2014-03-20,encodes,gene,protein,ERLIN2,ER lipid raft associated 2,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
NCBIGene:10613,RO:0002205,has gene product,NA,NA,UniProt:O75477,Q18035529,P688,Q21131645,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"In this case, abnormal erlin2 causes impaired ERAD of activated inositol 1,4,5-triphosphate (IP3) receptors and other substrates by compromising the structure of the erlin1/2 complex.",2014-03-20,encodes,gene,protein,ERLIN1,ER lipid raft associated 1,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
Reactome:R-HSA-8866522,BFO:0000050,is part of,NA,NA,Reactome:R-HSA-8866531,Q29017201,P361,Q29017203,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"In this case, abnormal erlin2 causes impaired ERAD of activated inositol 1,4,5-triphosphate (IP3) receptors and other substrates by compromising the structure of the erlin1/2 complex.",2014-03-20,is_component_of,protein complex,protein complex,erlin1/2 complex,ERAD complex,NA,http://www.reactome.org/content/detail/R-HSA-8866531,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
NCBIGene:81790,RO:0002331,involved in,NA,NA,Reactome:R-HSA-532668,Q18047094,P361,Q29017194,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"Recently, disorders associated with components of the ERAD pathway involving the Golgi apparatus, ER lipid raft-associated protein 1/2 (erlin1/2) complex, and E3-ubiquitin ligase have been identified.(...). Utimately, IP3 receptors undergo rapid degradation via the ubiquitin-proteasome pathway in response to cell stimulation. Evidence suggests that RNF170, an E3-ubiquitin ligase, mediates ubiquitination and processing of the IP3 receptor via interaction involving the erlin1/2 complex.",2014-03-20,participates,gene,pathway,RNF170,ERAD pathway,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
NCBIGene:81790,RO:0002205,has gene product,NA,NA,UniProt:Q96K19,Q18047094,P688,Q21124972,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"Recently, disorders associated with components of the ERAD pathway involving the Golgi apparatus, ER lipid raft-associated protein 1/2 (erlin1/2) complex, and E3-ubiquitin ligase have been identified.(...). Utimately, IP3 receptors undergo rapid degradation via the ubiquitin-proteasome pathway in response to cell stimulation. Evidence suggests that RNF170, an E3-ubiquitin ligase, mediates ubiquitination and processing of the IP3 receptor via interaction involving the erlin1/2 complex.",2014-03-20,encodes,gene,protein,RNF170,E3-ubiquitin ligase,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
NCBIGene:81790,RO:0002331,involved in,NA,NA,GO:0016567,Q18047094,P682,Q14860452,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"Recently, disorders associated with components of the ERAD pathway involving the Golgi apparatus, ER lipid raft-associated protein 1/2 (erlin1/2) complex, and E3-ubiquitin ligase have been identified.(...). Utimately, IP3 receptors undergo rapid degradation via the ubiquitin-proteasome pathway in response to cell stimulation. Evidence suggests that RNF170, an E3-ubiquitin ligase, mediates ubiquitination and processing of the IP3 receptor via interaction involving the erlin1/2 complex.",2014-03-20,participates,gene,biological process,RNF170,ubiquitination,NA,http://www.uniprot.org/uniprot/Q96K19,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
UniProt:Q96K19,RO:0002434,interacts with,NA,NA,Reactome:R-HSA-8866522,Q21124972,P129,Q29017201,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"Recently, disorders associated with components of the ERAD pathway involving the Golgi apparatus, ER lipid raft-associated protein 1/2 (erlin1/2) complex, and E3-ubiquitin ligase have been identified.(...). Utimately, IP3 receptors undergo rapid degradation via the ubiquitin-proteasome pathway in response to cell stimulation. Evidence suggests that RNF170, an E3-ubiquitin ligase, mediates ubiquitination and processing of the IP3 receptor via interaction involving the erlin1/2 complex.",2014-03-20,interacts,protein,protein complex,E3-ubiquitin ligase,erlin1/2 complex,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
NCBIGene:81790,RO:0002200,has phenotype,NA,NA,OMIM:608984,Q18047094,P2293,Q29017155,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"Mutation in RNF170 cause a late-onset autosomal dominant sensory ataxia characterized by distal sensory loss, diminished to absent reflexes, wide-based gait, and normal brain imaging. ",2014-03-20,associates,gene,disease,RNF170,late-onset autosomal dominant sensory ataxia,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
OMIM:608984,RO:0002200,has phenotype,NA,NA,HP:0003409,Q29017155,P1557,Q29019839,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"Mutation in RNF170 cause a late-onset autosomal dominant sensory ataxia characterized by distal sensory loss, diminished to absent reflexes, wide-based gait, and normal brain imaging. ",2014-03-20,presents,disease,phenotype,late-onset autosomal dominant sensory ataxia,distal sensory loss,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
OMIM:608984,RO:0002200,has phenotype,NA,NA,HP:0001284,Q29017155,P1557,Q640882,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"Mutation in RNF170 cause a late-onset autosomal dominant sensory ataxia characterized by distal sensory loss, diminished to absent reflexes, wide-based gait, and normal brain imaging. ",2014-03-20,presents,disease,phenotype,late-onset autosomal dominant sensory ataxia,diminished to absent reflexes,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
OMIM:608984,RO:0002200,has phenotype,NA,NA,HP:0002136,Q29017155,P1557,Q29019719,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"Mutation in RNF170 cause a late-onset autosomal dominant sensory ataxia characterized by distal sensory loss, diminished to absent reflexes, wide-based gait, and normal brain imaging. ",2014-03-20,presents,disease,phenotype,late-onset autosomal dominant sensory ataxia,wide-based gait,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
UniProt:Q96K19,RO:0002200,has phenotype,NA,NA,DOID:10595,Q21124972,P2293,Q1052687,https://www.ncbi.nlm.nih.gov/pubmed/24651605,Abnormal E3-ubiquitin ligase activity has also been postulated to play a role in the pathogenesis of an autosomal dominant form of Charcot-Marie-Tooth disease.,2014-03-20,associates,protein,disease,E3-ubiquitin ligase,autosomal dominant form of Charcot-Marie-Tooth disease,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
NCBIGene:81790,RO:0002434,interacts with,NA,NA,NCBIGene:11160,Q18047094,P129,Q18036170,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"Recently, disorders associated with components of the ERAD pathway involving the Golgi apparatus, ER lipid raft-associated protein 1/2 (erlin1/2) complex, and E3-ubiquitin ligase have been identified.(...). Utimately, IP3 receptors undergo rapid degradation via the ubiquitin-proteasome pathway in response to cell stimulation. Evidence suggests that RNF170, an E3-ubiquitin ligase, mediates ubiquitination and processing of the IP3 receptor via interaction involving the erlin1/2 complex.",2014-03-20,interacts,gene,gene,RNF170,ERLIN2,NA,https://thebiogrid.org/123583,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
NCBIGene:81790,RO:0002434,interacts with,NA,NA,NCBIGene:10613,Q18047094,P129,Q18035529,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"Recently, disorders associated with components of the ERAD pathway involving the Golgi apparatus, ER lipid raft-associated protein 1/2 (erlin1/2) complex, and E3-ubiquitin ligase have been identified.(...). Utimately, IP3 receptors undergo rapid degradation via the ubiquitin-proteasome pathway in response to cell stimulation. Evidence suggests that RNF170, an E3-ubiquitin ligase, mediates ubiquitination and processing of the IP3 receptor via interaction involving the erlin1/2 complex.",2014-03-20,interacts,gene,gene,RNF170,ERLIN1,NA,https://thebiogrid.org/123583,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
NCBIGene:55768,RO:HOM0000017,in orthology relationship with,NA,NA,NCBIGene:173028,Q18042037,P684,Q27542287,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"A study in Caenorhabditis elegans detected peripheral nervous system defects, including aberrant neuronal branching, in animals with loss-of-function mutations in png-1 the ortholog of NGLY1.",2014-03-20,ortholog_of,gene,gene,NGLY1,PNG1,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
SO:0001587,GENO:0000418,has affected feature,NA,NA,NCBIGene:173028,Q28371788,P361,Q27542287,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"A study in Caenorhabditis elegans detected peripheral nervous system defects, including aberrant neuronal branching, in animals with loss-of-function mutations in png-1 the ortholog of NGLY1.",2014-03-20,in_gene,variant class,gene,nonsense mutation|loss of function mutation|inactivating mutation|stop-gain mutation,PNG1,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
NCBIGene:173028,RO:0002162,in taxon,NA,NA,NCBITaxon:6239,Q27542287,P684,Q91703,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"A study in Caenorhabditis elegans detected peripheral nervous system defects, including aberrant neuronal branching, in animals with loss-of-function mutations in png-1 the ortholog of NGLY1.",2014-03-20,in_taxon,gene,taxon,PNG1,Caenorhabditis elegans,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
NCBIGene:173028,RO:0002200,has phenotype,NA,NA,HP:0500032,Q27542287,P2293,Q29017229,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"A study in Caenorhabditis elegans detected peripheral nervous system defects, including aberrant neuronal branching, in animals with loss-of-function mutations in png-1 the ortholog of NGLY1.",2014-03-20,associates,gene,phenotype,PNG1,Neuronal branching abnormalities|Aberrant neuronal branching,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
HP:0500032,PATO:0001668,associated with,NA,NA,HP:0009830,Q29017229,P2293,Q18556979,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"Neuronal branching abnormalities possibly relate to the peripheral neuropathy that seems to be relatively common in NGLY1 deficiency, but further studies are needed to determine the underlying pathogenesis of both central and peripheral nervous system abnormalities found in our patients.",2014-03-20,associates,phenotype,phenotype,Neuronal branching abnormalities|Aberrant neuronal branching,Peripheral neuropathy,NA,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0001263,Q28024539,P1557,Q1142806,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"The clinical and molecular findings demonstrate clear clinical similarities of patients with NGLY1 deficiency, although some variation in overall severity was observed, with the most common mutation being associated with more severe outcomes (Table 1). All patients had developmental delay, a movement disorder, and hypotonia. Other common findings included hypolacrima or alacrima (7/8), electroencephalography (EEG) abnormalities (7/8), elevated liver transaminases (6/7), microcephaly (6/8), abnormal brain imaging (6/8), diminished reflexes (6/8), hepatocyte cytoplasmic storage material or vacuolization (5/6), seizures (4/8), and abnormal nerve conduction (3/3) (Figure 1). ",2014-03-20,presents,disease,phenotype,NGLY1 deficiency,Developmental delay,8/8,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0004305,Q28024539,P1557,Q2608695,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"The clinical and molecular findings demonstrate clear clinical similarities of patients with NGLY1 deficiency, although some variation in overall severity was observed, with the most common mutation being associated with more severe outcomes (Table 1). All patients had developmental delay, a movement disorder, and hypotonia. Other common findings included hypolacrima or alacrima (7/8), electroencephalography (EEG) abnormalities (7/8), elevated liver transaminases (6/7), microcephaly (6/8), abnormal brain imaging (6/8), diminished reflexes (6/8), hepatocyte cytoplasmic storage material or vacuolization (5/6), seizures (4/8), and abnormal nerve conduction (3/3) (Figure 1). ",2014-03-20,presents,disease,phenotype,NGLY1 deficiency,Movement disorder,8/8,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0001252,Q28024539,P1557,Q1753547,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"The clinical and molecular findings demonstrate clear clinical similarities of patients with NGLY1 deficiency, although some variation in overall severity was observed, with the most common mutation being associated with more severe outcomes (Table 1). All patients had developmental delay, a movement disorder, and hypotonia. Other common findings included hypolacrima or alacrima (7/8), electroencephalography (EEG) abnormalities (7/8), elevated liver transaminases (6/7), microcephaly (6/8), abnormal brain imaging (6/8), diminished reflexes (6/8), hepatocyte cytoplasmic storage material or vacuolization (5/6), seizures (4/8), and abnormal nerve conduction (3/3) (Figure 1). ",2014-03-20,presents,disease,phenotype,NGLY1 deficiency,Hypotonia,8/8,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0000522,Q28024539,P1557,Q19595845,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"The clinical and molecular findings demonstrate clear clinical similarities of patients with NGLY1 deficiency, although some variation in overall severity was observed, with the most common mutation being associated with more severe outcomes (Table 1). All patients had developmental delay, a movement disorder, and hypotonia. Other common findings included hypolacrima or alacrima (7/8), electroencephalography (EEG) abnormalities (7/8), elevated liver transaminases (6/7), microcephaly (6/8), abnormal brain imaging (6/8), diminished reflexes (6/8), hepatocyte cytoplasmic storage material or vacuolization (5/6), seizures (4/8), and abnormal nerve conduction (3/3) (Figure 1). ",2014-03-20,presents,disease,phenotype,NGLY1 deficiency,Alacrima/hypolacrima,7/8,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0002353,Q28024539,P1557,Q29019794,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"The clinical and molecular findings demonstrate clear clinical similarities of patients with NGLY1 deficiency, although some variation in overall severity was observed, with the most common mutation being associated with more severe outcomes (Table 1). All patients had developmental delay, a movement disorder, and hypotonia. Other common findings included hypolacrima or alacrima (7/8), electroencephalography (EEG) abnormalities (7/8), elevated liver transaminases (6/7), microcephaly (6/8), abnormal brain imaging (6/8), diminished reflexes (6/8), hepatocyte cytoplasmic storage material or vacuolization (5/6), seizures (4/8), and abnormal nerve conduction (3/3) (Figure 1). ",2014-03-20,presents,disease,phenotype,NGLY1 deficiency,EGG abnormalities,7/8,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0002019,Q28024539,P1557,Q178436,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"NGLY1-deficient patients have a striking clinical triad, consisting of abnormal tear production, choreoathetosis, and liver disease. In addition, global developmental delay, acquired microcephaly, hypotonia, EEG abnormalities with or without overt seizures, brain imaging abnormalities, a peripheral neuropathy, constipation, and a history of IUGR were common findings. Some patients were noted to have dysmorphic features, but overall these were not considered to be particularly prominent (Table1).",2014-03-20,presents,disease,phenotype,NGLY1 deficiency,Constipation,7/8,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0002910,Q28024539,P1557,Q2448873,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"The clinical and molecular findings demonstrate clear clinical similarities of patients with NGLY1 deficiency, although some variation in overall severity was observed, with the most common mutation being associated with more severe outcomes (Table 1). All patients had developmental delay, a movement disorder, and hypotonia. Other common findings included hypolacrima or alacrima (7/8), electroencephalography (EEG) abnormalities (7/8), elevated liver transaminases (6/7), microcephaly (6/8), abnormal brain imaging (6/8), diminished reflexes (6/8), hepatocyte cytoplasmic storage material or vacuolization (5/6), seizures (4/8), and abnormal nerve conduction (3/3) (Figure 1). ",2014-03-20,presents,disease,phenotype,NGLY1 deficiency,Transaminase elevation,6/7,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0000252,Q28024539,P1557,Q431643,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"The clinical and molecular findings demonstrate clear clinical similarities of patients with NGLY1 deficiency, although some variation in overall severity was observed, with the most common mutation being associated with more severe outcomes (Table 1). All patients had developmental delay, a movement disorder, and hypotonia. Other common findings included hypolacrima or alacrima (7/8), electroencephalography (EEG) abnormalities (7/8), elevated liver transaminases (6/7), microcephaly (6/8), abnormal brain imaging (6/8), diminished reflexes (6/8), hepatocyte cytoplasmic storage material or vacuolization (5/6), seizures (4/8), and abnormal nerve conduction (3/3) (Figure 1). ",2014-03-20,presents,disease,phenotype,NGLY1 deficiency,Microcephaly,6/8,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0001265,Q28024539,P1557,Q1419356,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"The clinical and molecular findings demonstrate clear clinical similarities of patients with NGLY1 deficiency, although some variation in overall severity was observed, with the most common mutation being associated with more severe outcomes (Table 1). All patients had developmental delay, a movement disorder, and hypotonia. Other common findings included hypolacrima or alacrima (7/8), electroencephalography (EEG) abnormalities (7/8), elevated liver transaminases (6/7), microcephaly (6/8), abnormal brain imaging (6/8), diminished reflexes (6/8), hepatocyte cytoplasmic storage material or vacuolization (5/6), seizures (4/8), and abnormal nerve conduction (3/3) (Figure 1). ",2014-03-20,presents,disease,phenotype,NGLY1 deficiency,Decreased reflexes,6/8,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0012638 ,Q28024539,P1557,Q29019857,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"The clinical and molecular findings demonstrate clear clinical similarities of patients with NGLY1 deficiency, although some variation in overall severity was observed, with the most common mutation being associated with more severe outcomes (Table 1). All patients had developmental delay, a movement disorder, and hypotonia. Other common findings included hypolacrima or alacrima (7/8), electroencephalography (EEG) abnormalities (7/8), elevated liver transaminases (6/7), microcephaly (6/8), abnormal brain imaging (6/8), diminished reflexes (6/8), hepatocyte cytoplasmic storage material or vacuolization (5/6), seizures (4/8), and abnormal nerve conduction (3/3) (Figure 1). ",2014-03-20,presents,disease,phenotype,NGLY1 deficiency,Abnormal brain imaging,6/8,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0001392,Q28024539,P1557,Q29020078,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"The clinical and molecular findings demonstrate clear clinical similarities of patients with NGLY1 deficiency, although some variation in overall severity was observed, with the most common mutation being associated with more severe outcomes (Table 1). All patients had developmental delay, a movement disorder, and hypotonia. Other common findings included hypolacrima or alacrima (7/8), electroencephalography (EEG) abnormalities (7/8), elevated liver transaminases (6/7), microcephaly (6/8), abnormal brain imaging (6/8), diminished reflexes (6/8), hepatocyte cytoplasmic storage material or vacuolization (5/6), seizures (4/8), and abnormal nerve conduction (3/3) (Figure 1). ",2014-03-20,presents,disease,phenotype,NGLY1 deficiency,Abnormal liver storage,5/6,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0001511,Q28024539,P1557,Q29019673,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"NGLY1-deficient patients have a striking clinical triad, consisting of abnormal tear production, choreoathetosis, and liver disease. In addition, global developmental delay, acquired microcephaly, hypotonia, EEG abnormalities with or without overt seizures, brain imaging abnormalities, a peripheral neuropathy, constipation, and a history of IUGR were common findings. Some patients were noted to have dysmorphic features, but overall these were not considered to be particularly prominent (Table1).",2014-03-20,presents,disease,phenotype,NGLY1 deficiency,IUGR,5/8,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0002151,Q28024539,P1557,Q29019735,https://www.ncbi.nlm.nih.gov/pubmed/24651605,Table 1,2014-03-20,presents,disease,phenotype,NGLY1 deficiency,Elevetated blood lactate,4/6,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0001250,Q28024539,P1557,Q6279182,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"The clinical and molecular findings demonstrate clear clinical similarities of patients with NGLY1 deficiency, although some variation in overall severity was observed, with the most common mutation being associated with more severe outcomes (Table 1). All patients had developmental delay, a movement disorder, and hypotonia. Other common findings included hypolacrima or alacrima (7/8), electroencephalography (EEG) abnormalities (7/8), elevated liver transaminases (6/7), microcephaly (6/8), abnormal brain imaging (6/8), diminished reflexes (6/8), hepatocyte cytoplasmic storage material or vacuolization (5/6), seizures (4/8), and abnormal nerve conduction (3/3) (Figure 1). ",2014-03-20,presents,disease,phenotype,NGLY1 deficiency,Seizures,4/8,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0000486,Q28024539,P1557,Q179951,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"Patient 4: (...). In addtion, global developmental delay, abnormal tear production, unilateral ptosis, strabismus, elevated liver transaminases (three to four times upper limit of normal), and constipation were noted in infancy.",2014-03-20,presents,disease,phenotype,NGLY1 deficiency,Strabismus,4/8,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0012804,Q28024539,P1557,Q1628473,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"Patient 1: (...). He has cortical vision impairment and congenital alacrima, and corneal ulcerations with scarring were noted at the age of 4 years.",2014-03-20,presents,disease,phenotype,NGLY1 deficiency,Corneal disease,4/8,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0010605,Q28024539,P1557,Q769595,https://www.ncbi.nlm.nih.gov/pubmed/24651605,Table 1,2014-03-20,presents,disease,phenotype,NGLY1 deficiency,Chalazions,4/8,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0000657,Q28024539,P1557,Q2074059,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"Patient 2: (...). At 5 years of age, she was noted to have ocular apraxia, distal tapering of hands and feet, and diminished deep tendon reflexes.",2014-03-20,presents,disease,phenotype,NGLY1 deficiency,Ocular apraxia,4/8,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0006579,Q28024539,P1557,Q1755487,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"Patient 7: a now 3-year-old girl, was born at term via scheduled Cesarean section and, other than mild jaundice, did not have any neonatal complications. ",2014-03-20,presents,disease,phenotype,NGLY1 deficiency,Neonatal Jaundice,4/8,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0001999 ,Q28024539,P1557,Q29019704,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"NGLY1-deficient patients have a striking clinical triad, consisting of abnormal tear production, choreoathetosis, and liver disease. In addition, global developmental delay, acquired microcephaly, hypotonia, EEG abnormalities with or without overt seizures, brain imaging abnormalities, a peripheral neuropathy, constipation, and a history of IUGR were common findings. Some patients were noted to have dysmorphic features, but overall these were not considered to be particularly prominent (Table1).",2014-03-20,presents,disease,phenotype,NGLY1 deficiency,Dysmorphic features,4/8,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0002650,Q28024539,P1557,Q174857,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"Patient 8: (...). Other medical history includes acquired microcephaly, an inability to completely close her eyes during sleep, chronic conjunctivitis, corneal clouding, hypolacrima, strabismus, hearing impairment, gastro-esophageal reflux, chronic constipation, severe scoliosis, and talipes equinovarus.",2014-03-20,presents,disease,phenotype,NGLY1 deficiency,Scoliosis,4/8,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0200055,Q28024539,P1557,Q29019862,https://www.ncbi.nlm.nih.gov/pubmed/24651605,Table 1,2014-03-20,presents,disease,phenotype,NGLY1 deficiency,Small hands,4/8,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0001773,Q28024539,P1557,Q29019700,https://www.ncbi.nlm.nih.gov/pubmed/24651605,Table 1,2014-03-20,presents,disease,phenotype,NGLY1 deficiency,Small feet,4/8,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0009830,Q28024539,P1557,Q18556979,https://www.ncbi.nlm.nih.gov/pubmed/24651605,"NGLY1-deficient patients have a striking clinical triad, consisting of abnormal tear production, choreoathetosis, and liver disease. In addition, global developmental delay, acquired microcephaly, hypotonia, EEG abnormalities with or without overt seizures, brain imaging abnormalities, a peripheral neuropathy, constipation, and a history of IUGR were common findings. Some patients were noted to have dysmorphic features, but overall these were not considered to be particularly prominent (Table1).",2014-03-20,presents,disease,phenotype,NGLY1 deficiency,Peripheral neuropathy,3/3,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0006254,Q28024539,P1557,Q5359683,https://www.ncbi.nlm.nih.gov/pubmed/24651605,Table 1,2014-03-20,presents,disease,phenotype,NGLY1 deficiency,Elevated AFP,3/5,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0006958,Q28024539,P1557,Q29019841,https://www.ncbi.nlm.nih.gov/pubmed/24651605,Table 1,2014-03-20,presents,disease,phenotype,NGLY1 deficiency,ABR abnormalities,2/5,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
DOID:0060728,RO:0002200,has phenotype,NA,NA,HP:0001395,Q28024539,P1557,Q147778,https://www.ncbi.nlm.nih.gov/pubmed/24651605,Table 1,2014-03-20,presents,disease,phenotype,NGLY1 deficiency,Liver fibrosis,2/6,NA,2017-03-22,http://orcid.org/0000-0003-0169-8159,NA
NCBIGene:11826,RO:HOM0000017,in orthology relationship with,NA,NA,FlyBase:FBgn0000180,Q14905239,P684,NA,NA,NA,NA,NA,gene,gene,Aqp1,bib,NA,https://monarchinitiative.org/gene/MGI%3A103201#ortholog-phenotypes,2017-11-16,http://orcid.org/0000-0003-0169-8159,NA
FlyBase:FBgn0000180,RO:0002200,has phenotype,NA,NA,FBcv:0000435,NA,P2293,NA,NA,NA,NA,NA,gene,phenotype,bib,neuroanatomy defective,NA,https://monarchinitiative.org/gene/MGI%3A103201#ortholog-phenotypes,2017-11-16,http://orcid.org/0000-0003-0169-8159,2n shell node edge
KEGG-path:map04141,RO:0002200,has phenotype,NA,NA,DOID:0060728,Q30032991,P2293,Q28024539,NA,NA,NA,NA,pathway,disease,Protein processing in endoplasmic reticulum,NGLY1 deficiency,NA,http://www.genome.jp/dbget-bin/www_bget?pathway:map04141,2017-11-16,http://orcid.org/0000-0003-0169-8159,NA
CHEBI:506227,skos:exactMatch,exact match,NA,NA,HMDB:HMDB00215,Q27225758,P2888,Q27225758,NA,NA,NA,sameAs,chemical compound,chemical compound,GlcNAc,GlcNAc,NA,http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:506227,05-18-2017,http://orcid.org/0000-0003-0169-8159,NA
CHEBI:506227,rdfs:seeAlso,see also,NA,NA,DrugBank:DB00141,Q27225758,P715,Q284367,NA,NA,NA,xref,chemical compound,pharmaceutical drug,GlcNAc,GlcNAc,NA,http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:506227,05-18-2017,http://orcid.org/0000-0003-0169-8159,NA
CHEBI:17411,skos:exactMatch,exact match,NA,NA,DrugBank:DB00141,Q284367,P2888,Q284367,NA,NA,NA,sameAs,pharmaceutical drug,pharmaceutical drug,GlcNAc,GlcNAc,NA,http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:506227,05-18-2017,http://orcid.org/0000-0003-0169-8159,NA
CHEBI:506227,RO:0002331,involved in,NA,NA,GO:0006040,Q27225758,P682,Q21136023,NA,NA,NA,BioFunction,chemical compound,biological_process,GlcNAc,Component of Aminosugars metabolism,NA,http://www.hmdb.ca/metabolites/HMDB00215,05-18-2017,http://orcid.org/0000-0003-0169-8159,NA
CHEBI:506227,RO:0002331,involved in,NA,NA,GO:0006536,Q27225758,P682,Q14873651,NA,NA,NA,BioFunction,chemical compound,biological_process,GlcNAc,Component of Glutamate metabolism,NA,http://www.hmdb.ca/metabolites/HMDB00215,05-18-2017,http://orcid.org/0000-0003-0169-8159,NA
CHEBI:506227,RO:0002331,involved in,NA,NA,GO:0018146,Q27225758,P682,Q21102399,NA,NA,NA,BioFunction,chemical compound,biological_process,GlcNAc,Component of Keratan sulfate biosynthesis,NA,http://www.hmdb.ca/metabolites/HMDB00215,05-18-2017,http://orcid.org/0000-0003-0169-8159,NA
CHEBI:506227,RO:0002331,involved in,NA,NA,GO:0035528,Q27225758,P682,Q22281219,NA,NA,NA,BioFunction,chemical compound,biological_process,GlcNAc,Component of N-Glycan biosynthesis,NA,http://www.hmdb.ca/metabolites/HMDB00215,05-18-2017,http://orcid.org/0000-0003-0169-8159,NA
CHEBI:506227,RO:0002331,involved in,NA,NA,FOODON:03401298,Q27225758,P680,Q645858,NA,NA,NA,BioFunction,chemical compound,molecular function,GlcNAc,Dietary supplement,NA,http://www.hmdb.ca/metabolites/HMDB00215,05-18-2017,http://orcid.org/0000-0003-0169-8159,NA
CHEBI:506227,RO:0002331,involved in,NA,NA,CHEBI:27027,Q27225758,P680,Q531507,NA,NA,NA,BioFunction,chemical compound,molecular function,GlcNAc,Micronutrient,NA,http://www.hmdb.ca/metabolites/HMDB00215,05-18-2017,http://orcid.org/0000-0003-0169-8159,NA
CHEBI:506227,BFO:0000050,is part of,NA,NA,GO:0005737,Q27225758,P681,Q79899,NA,NA,NA,located,chemical compound,cell component,GlcNAc,Cytoplasm,NA,http://www.hmdb.ca/metabolites/HMDB00215,05-18-2017,http://orcid.org/0000-0003-0169-8159,NA
CHEBI:506227,BFO:0000050,is part of,NA,NA,GO:0016020,Q27225758,P681,Q14349455,NA,NA,NA,located,chemical compound,cell component,GlcNAc,Membrane,NA,http://www.hmdb.ca/metabolites/HMDB00215,05-18-2017,http://orcid.org/0000-0003-0169-8159,NA
CHEBI:506227,BFO:0000050,is part of,NA,NA,GO:0005764,Q27225758,P681,Q83330,NA,NA,NA,located,chemical compound,cell component,GlcNAc,Lysosome,NA,http://www.hmdb.ca/metabolites/HMDB00215,05-18-2017,http://orcid.org/0000-0003-0169-8159,NA
CHEBI:506227,BFO:0000050,is part of,NA,NA,UBERON:0000178,Q27225758,P681,Q7873,NA,NA,NA,located,chemical compound,anatomy (biofluid),GlcNAc,Blood,NA,http://www.hmdb.ca/metabolites/HMDB00215,05-18-2017,http://orcid.org/0000-0003-0169-8159,NA
CHEBI:506227,BFO:0000050,is part of,NA,NA,UBERON:0001913,Q27225758,P681,Q22728,NA,NA,NA,located,chemical compound,anatomy (biofluid),GlcNAc,Breast Milk,NA,http://www.hmdb.ca/metabolites/HMDB00215,05-18-2017,http://orcid.org/0000-0003-0169-8159,NA
CHEBI:506227,BFO:0000050,is part of,NA,NA,UBERON:0001988,Q27225758,P681,Q496,NA,NA,NA,located,chemical compound,anatomy (biofluid),GlcNAc,Feces,NA,http://www.hmdb.ca/metabolites/HMDB00215,05-18-2017,http://orcid.org/0000-0003-0169-8159,NA
CHEBI:506227,BFO:0000050,is part of,NA,NA,UBERON:0001836,Q27225758,P681,Q155925,NA,NA,NA,located,chemical compound,anatomy (biofluid),GlcNAc,Saliva,NA,http://www.hmdb.ca/metabolites/HMDB00215,05-18-2017,http://orcid.org/0000-0003-0169-8159,NA
CHEBI:506227,BFO:0000050,is part of,NA,NA,UBERON:0001088,Q27225758,P681,Q40924,NA,NA,NA,located,chemical compound,anatomy (biofluid),GlcNAc,Urine,NA,http://www.hmdb.ca/metabolites/HMDB00215,05-18-2017,http://orcid.org/0000-0003-0169-8159,NA
CHEBI:506227,BFO:0000050,is part of,NA,NA,UBERON:0000160,Q27225758,P681,Q9639,NA,NA,NA,located,chemical compound,anatomy (tissue),GlcNAc,Intestine,NA,http://www.hmdb.ca/metabolites/HMDB00215,05-18-2017,http://orcid.org/0000-0003-0169-8159,NA
CHEBI:506227,BFO:0000050,is part of,NA,NA,UBERON:0000345,Q27225758,P681,Q187388,NA,NA,NA,located,chemical compound,anatomy (tissue),GlcNAc,Myelin,NA,http://www.hmdb.ca/metabolites/HMDB00215,05-18-2017,http://orcid.org/0000-0003-0169-8159,NA
CHEBI:506227,BFO:0000050,is part of,NA,NA,CL:0000233,Q27225758,P681,Q101026,NA,NA,NA,located,chemical compound,anatomy (tissue),GlcNAc,Platelet,NA,http://www.hmdb.ca/metabolites/HMDB00215,05-18-2017,http://orcid.org/0000-0003-0169-8159,NA
CHEBI:506227,BFO:0000050,is part of,NA,NA,UBERON:0002367,Q27225758,P681,Q9625,NA,NA,NA,located,chemical compound,anatomy (tissue),GlcNAc,Prostate,NA,http://www.hmdb.ca/metabolites/HMDB00215,05-18-2017,http://orcid.org/0000-0003-0169-8159,NA
CHEBI:506227,RO:0002434,interacts with,NA,NA,UniProt:Q9Y223,Q27225758,P129,Q21106661,NA,NA,NA,interacts,chemical compound,protein (enzymes),GlcNAc,NA,NA,http://www.hmdb.ca/metabolites/HMDB00215,05-18-2017,http://orcid.org/0000-0003-0169-8159,NA
CHEBI:506227,RO:0002434,interacts with,NA,NA,UniProt:P51606,Q27225758,P129,Q22677897,NA,NA,NA,interacts,chemical compound,protein (enzymes),GlcNAc,NA,NA,http://www.hmdb.ca/metabolites/HMDB00215,05-18-2017,http://orcid.org/0000-0003-0169-8159,NA
CHEBI:506227,RO:0002434,interacts with,NA,NA,UniProt:O60909,Q27225758,P129,Q21108255,NA,NA,NA,interacts,chemical compound,protein (enzymes),GlcNAc,NA,NA,http://www.hmdb.ca/metabolites/HMDB00215,05-18-2017,http://orcid.org/0000-0003-0169-8159,NA
CHEBI:506227,RO:0002434,interacts with,NA,NA,UniProt:P15291,Q27225758,P129,Q21112774,NA,NA,NA,interacts,chemical compound,protein (enzymes),GlcNAc,NA,NA,http://www.hmdb.ca/metabolites/HMDB00215,05-18-2017,http://orcid.org/0000-0003-0169-8159,NA
CHEBI:506227,RO:0002434,interacts with,NA,NA,UniProt:P07686,Q27225758,P129,Q5629497,NA,NA,NA,interacts,chemical compound,protein (enzymes),GlcNAc,NA,NA,http://www.hmdb.ca/metabolites/HMDB00215,05-18-2017,http://orcid.org/0000-0003-0169-8159,NA
CHEBI:506227,RO:0002434,interacts with,NA,NA,UniProt:P06865,Q27225758,P129,Q21120577,NA,NA,NA,interacts,chemical compound,protein (enzymes),GlcNAc,NA,NA,http://www.hmdb.ca/metabolites/HMDB00215,05-18-2017,http://orcid.org/0000-0003-0169-8159,NA
CHEBI:506227,RO:0002434,interacts with,NA,NA,UniProt:Q9UJ70,Q27225758,P129,Q21105246,NA,NA,NA,interacts,chemical compound,protein (enzymes),GlcNAc,NA,NA,http://www.hmdb.ca/metabolites/HMDB00215,05-18-2017,http://orcid.org/0000-0003-0169-8159,NA
CHEBI:506227,RO:0002434,interacts with,NA,NA,UniProt:Q9BZP6,Q27225758,P129,Q21100758,NA,NA,NA,interacts,chemical compound,protein (enzymes),GlcNAc,NA,NA,http://www.hmdb.ca/metabolites/HMDB00215,05-18-2017,http://orcid.org/0000-0003-0169-8159,NA
CHEBI:506227,RO:0002434,interacts with,NA,NA,UniProt:Q9UK23,Q27225758,P129,Q22678770,NA,NA,NA,interacts,chemical compound,protein (enzymes),GlcNAc,NA,NA,http://www.hmdb.ca/metabolites/HMDB00215,05-18-2017,http://orcid.org/0000-0003-0169-8159,NA
CHEBI:506227,RO:0002434,interacts with,NA,NA,UniProt:Q13231,Q27225758,P129,Q21117216,NA,NA,NA,interacts,chemical compound,protein (enzymes),GlcNAc,NA,NA,http://www.hmdb.ca/metabolites/HMDB00215,05-18-2017,http://orcid.org/0000-0003-0169-8159,NA
CHEBI:506227,RO:0002434,interacts with,NA,NA,UniProt:O60512 ,Q27225758,P129,Q21108250,NA,NA,NA,interacts,chemical compound,protein (enzymes),GlcNAc,NA,NA,http://www.hmdb.ca/metabolites/HMDB00215,05-18-2017,http://orcid.org/0000-0003-0169-8159,NA
CHEBI:506227,RO:0002434,interacts with,NA,NA,UniProt:O60513,Q27225758,P129,Q21112769,NA,NA,NA,interacts,chemical compound,protein (enzymes),GlcNAc,NA,NA,http://www.hmdb.ca/metabolites/HMDB00215,05-18-2017,http://orcid.org/0000-0003-0169-8159,NA
CHEBI:506227,RO:0002434,interacts with,NA,NA,UniProt:P54802,Q27225758,P129,Q22678008,NA,NA,NA,interacts,chemical compound,protein (enzymes),GlcNAc,NA,NA,http://www.hmdb.ca/metabolites/HMDB00215,05-18-2017,http://orcid.org/0000-0003-0169-8159,NA
CHEBI:506227,RO:0002434,interacts with,NA,NA,UniProt:P61626,Q27225758,P129,Q21114915,NA,NA,NA,interacts,chemical compound,protein (enzymes),GlcNAc,NA,NA,http://www.hmdb.ca/metabolites/HMDB00215,05-18-2017,http://orcid.org/0000-0003-0169-8159,NA
CHEBI:506227,RO:0002434,interacts with,NA,NA,UniProt:Q8WZA1,Q27225758,P129,Q21133271,NA,NA,NA,interacts,chemical compound,protein (enzymes),GlcNAc,NA,NA,http://www.hmdb.ca/metabolites/HMDB00215,05-18-2017,http://orcid.org/0000-0003-0169-8159,NA
CHEBI:506227,RO:0002434,interacts with,NA,NA,UniProt:Q6UWQ5,Q27225758,P129,Q21122346,NA,NA,NA,interacts,chemical compound,protein (enzymes),GlcNAc,NA,NA,http://www.hmdb.ca/metabolites/HMDB00215,05-18-2017,http://orcid.org/0000-0003-0169-8159,NA
CHEBI:506227,RO:0002434,interacts with,NA,NA,UniProt:Q7Z4W2,Q27225758,P129,Q21122348,NA,NA,NA,interacts,chemical compound,protein (enzymes),GlcNAc,NA,NA,http://www.hmdb.ca/metabolites/HMDB00215,05-18-2017,http://orcid.org/0000-0003-0169-8159,NA
CHEBI:506227,RO:0002434,interacts with,NA,NA,UniProt:Q96QH8,Q27225758,P129,Q21122354,NA,NA,NA,interacts,chemical compound,protein (enzymes),GlcNAc,NA,NA,http://www.hmdb.ca/metabolites/HMDB00215,05-18-2017,http://orcid.org/0000-0003-0169-8159,NA
CHEBI:506227,RO:0002434,interacts with,NA,NA,UniProt:O75951,Q27225758,P129,Q21122344,NA,NA,NA,interacts,chemical compound,protein (enzymes),GlcNAc,NA,NA,http://www.hmdb.ca/metabolites/HMDB00215,05-18-2017,http://orcid.org/0000-0003-0169-8159,NA
CHEBI:506227,RO:0002434,interacts with,NA,NA,UniProt:P36222,Q27225758,P129,Q21117210,NA,NA,NA,interacts,chemical compound,protein (enzymes),GlcNAc,NA,NA,http://www.hmdb.ca/metabolites/HMDB00215,05-18-2017,http://orcid.org/0000-0003-0169-8159,NA
CHEBI:506227,RO:0002434,interacts with,NA,NA,UniProt:Q15782,Q27225758,P129,Q21117212,NA,NA,NA,interacts,chemical compound,protein (enzymes),GlcNAc,NA,NA,http://www.hmdb.ca/metabolites/HMDB00215,05-18-2017,http://orcid.org/0000-0003-0169-8159,NA
CHEBI:506227,RO:0002434,interacts with,NA,NA,UniProt:Q8WVB3,Q27225758,P129,Q21120600,NA,NA,NA,interacts,chemical compound,protein (enzymes),GlcNAc,NA,NA,http://www.hmdb.ca/metabolites/HMDB00215,05-18-2017,http://orcid.org/0000-0003-0169-8159,NA
CHEBI:506227,RO:0002434,interacts with,NA,NA,UniProt:O60502,Q27225758,P129,Q22676717,NA,NA,NA,interacts,chemical compound,protein (enzymes),GlcNAc,NA,NA,http://www.hmdb.ca/metabolites/HMDB00215,05-18-2017,http://orcid.org/0000-0003-0169-8159,NA
CHEBI:506227,RO:0002331,involved in,NA,NA,GO:0097316,Q27225758,P682,Q22273441,NA,NA,NA,participates,chemical compound,biological process,GlcNAc,cellular response to N-acetyl-D-glucosamine,NA,https://scigraph-ontology.monarchinitiative.org/scigraph/graph/neighbors/CHEBI:506227,05-18-2017,http://orcid.org/0000-0003-0169-8159,NA
CHEBI:506227,RO:0002331,involved in,NA,NA,GO:0097315,Q27225758,P682,Q22273440,NA,NA,NA,participates,chemical compound,biological process,GlcNAc,response to N-acetyl-D-glucosamine,NA,https://scigraph-ontology.monarchinitiative.org/scigraph/graph/neighbors/CHEBI:506227,05-18-2017,http://orcid.org/0000-0003-0169-8159,NA
CHEBI:506227,RO:0000087,has role,NA,NA,CHEBI:78366,Q27225758,P2868,Q29994324,NA,NA,NA,has biological role,chemical compound,biological role,GlcNAc,EC 2.7.1.1 (hexokinase) inhibitor,NA,http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:506227,05-18-2017,http://orcid.org/0000-0003-0169-8159,NA
CHEBI:506227,RO:0000087,has role,NA,NA,CHEBI:76969,Q27225758,P2868,Q29994327,NA,NA,NA,has biological role,chemical compound,biological role,GlcNAc,bacterial metabolite,NA,http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:506227,05-18-2017,http://orcid.org/0000-0003-0169-8159,NA
CHEBI:506227,RO:0002434,interacts with,NA,NA,UniProt:P00811,Q27225758,P129,Q24138857,NA,NA,NA,interacts,chemical compound,protein (enzymes),GlcNAc,NA,NA,https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL240524,05-18-2017,http://orcid.org/0000-0003-0169-8159,NA
CHEBI:506227,RO:0002434,interacts with,NA,NA,UniProt:P27695,Q27225758,P129,Q22676734,NA,NA,NA,interacts,chemical compound,protein (enzymes),GlcNAc,NA,NA,https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL240524,05-18-2017,http://orcid.org/0000-0003-0169-8159,NA
CHEBI:506227,RO:0002434,interacts with,NA,NA,UniProt:O75874,Q27225758,P129,Q21116029,NA,NA,NA,interacts,chemical compound,protein (enzymes),GlcNAc,NA,NA,https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL240524,05-18-2017,http://orcid.org/0000-0003-0169-8159,NA
CHEBI:506227,RO:0002434,interacts with,NA,NA,UniProt:Q6P4F1,Q27225758,P129,Q21110287,NA,NA,NA,interacts,chemical compound,protein (enzymes),GlcNAc,NA,NA,https://www.ebi.ac.uk/chembldb/compound/inspect/CHEMBL240524,05-18-2017,http://orcid.org/0000-0003-0169-8159,NA
CHEBI:506227,RO:0002331,involved in,NA,NA,KEGG-path:map00520,Q27225758,P361,Q30032774,NA,NA,NA,participates,chemical compound,pathway,GlcNAc,Amino sugar and nucleotide sugar metabolism,NA,http://www.hmdb.ca/metabolites/HMDB00215,05-18-2017,http://orcid.org/0000-0003-0169-8159,NA
CHEBI:506227,RO:0002331,involved in,NA,NA,KEGG-path:map00520,Q27225758,P361,Q30032774,NA,NA,NA,participates,chemical compound,pathway,GlcNAc,Amino sugar and nucleotide sugar metabolism,NA,http://www.genome.jp/dbget-bin/www_bget?cpd:C00140,05-18-2017,http://orcid.org/0000-0003-0169-8159,NA
CHEBI:506227,RO:0002331,involved in,NA,NA,KEGG-path:map01100,Q27225758,P361,Q30032846,NA,NA,NA,participates,chemical compound,pathway,GlcNAc,Metabolic pathways,NA,http://www.genome.jp/dbget-bin/www_bget?cpd:C00140,05-18-2017,http://orcid.org/0000-0003-0169-8159,NA
CHEBI:506227,RO:0002331,involved in,NA,NA,KEGG-path:map02010,Q27225758,P361,Q30032872,NA,NA,NA,participates,chemical compound,pathway,GlcNAc,ABC transporters,NA,http://www.genome.jp/dbget-bin/www_bget?cpd:C00140,05-18-2017,http://orcid.org/0000-0003-0169-8159,NA
CHEBI:506227,RO:0002331,involved in,NA,NA,KEGG-path:map02060,Q27225758,P361,Q30032881,NA,NA,NA,participates,chemical compound,pathway,GlcNAc,Phosphotransferase system (PTS),NA,http://www.genome.jp/dbget-bin/www_bget?cpd:C00140,05-18-2017,http://orcid.org/0000-0003-0169-8159,NA
NCBIGene:55768,RO:0002331,involved in,NA,NA,Reactome:R-HSA-532668,Q18042037,P361,Q29017194,NA,NA,NA,participates,gene,pathway,NGLY1,N-glycan trimming in the ER and Calnexin/Calreticulin cycle,NA,https://monarchinitiative.org/gene/NCBIGene%3A55768#pathways,2017-11-16,http://orcid.org/0000-0003-0169-8159,I have only included the pathways from KEGG that seems are not retrievable edges from the Monarch API.
NCBIGene:55768,RO:0002331,involved in,NA,NA,KEGG-path:map04141,Q18042037,P361,Q30032991,NA,NA,NA,participates,gene,pathway,NGLY1,Protein processing in endoplasmic reticulum,NA,https://monarchinitiative.org/gene/NCBIGene%3A55768#pathways,2017-11-16,http://orcid.org/0000-0003-0169-8159,I have only included the pathways from KEGG that seems are not retrievable edges from the Monarch API.
